<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Med Insights Pathol</journal-id><journal-id journal-id-type="iso-abbrev">Clin Med Insights Pathol</journal-id><journal-id journal-id-type="pmc-domain-id">1396</journal-id><journal-id journal-id-type="pmc-domain">cpath</journal-id><journal-id journal-id-type="publisher-id">PAT</journal-id><journal-title-group><journal-title>Clinical Medicine Insights. Pathology</journal-title></journal-title-group><issn pub-type="epub">1179-5557</issn><publisher><publisher-name>SAGE Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC5398647</article-id><article-id pub-id-type="pmcid-ver">PMC5398647.1</article-id><article-id pub-id-type="pmcaid">5398647</article-id><article-id pub-id-type="pmcaiid">5398647</article-id><article-id pub-id-type="pmid">28469517</article-id><article-id pub-id-type="doi">10.1177/1179555717695548</article-id><article-id pub-id-type="publisher-id">10.1177_1179555717695548</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>A Little Help From the Follicles: Understanding the Germinal Center Response to Human Immunodeficiency Virus 1 Infection and Prophylactic Vaccines</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Gary</surname><given-names initials="EN">Ebony N</given-names></name><xref ref-type="aff" rid="aff1-1179555717695548">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kutzler</surname><given-names initials="MA">Michele A</given-names></name><xref ref-type="aff" rid="aff1-1179555717695548">1</xref><xref ref-type="aff" rid="aff2-1179555717695548">2</xref><xref ref-type="corresp" rid="corresp1-1179555717695548"/></contrib></contrib-group><aff id="aff1-1179555717695548"><label>1</label>Department of Microbiology and Immunology, College of Medicine, Drexel University, Philadelphia, PA, USA</aff><aff id="aff2-1179555717695548"><label>2</label>Department of Medicine, Division of Infectious Diseases &amp; HIV Medicine, College of Medicine, Drexel University, Philadelphia, PA, USA</aff><author-notes><corresp id="corresp1-1179555717695548">Michele A Kutzler, Dept. of Medicine; Division of Infectious Diseases and HIV Medicine Drexel University College of Medicine 245 North 15th Street Rm. 6206 Philadelphia, PA 19102, USA. Email: <email>mkutzler@drexelmed.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>10</volume><issue-id pub-id-type="pmc-issue-id">291175</issue-id><elocation-id>1179555717695548</elocation-id><history><date date-type="received"><day>23</day><month>6</month><year>2016</year></date><date date-type="accepted"><day>29</day><month>1</month><year>2017</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>03</month><year>2017</year></date></event><event event-type="pmc-live"><date><day>03</day><month>05</month><year>2017</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-11-04 01:25:10.350"><day>04</day><month>11</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">http://www.creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (<ext-link ext-link-type="uri" xlink:href="http://www.uk.sagepub.com/aboutus/openaccess.htm">http://www.uk.sagepub.com/aboutus/openaccess.htm</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_1179555717695548.pdf"/><abstract><p>Human immunodeficiency virus 1 (HIV-1) is the causative agent of AIDS. There are currently more than 35 million people living with HIV infection worldwide, and more than 2 million new infections occur each year. The global pandemic caused by HIV-1 is the subject of numerous research projects, with the development of a prophylactic vaccine and a therapeutic cure being the ultimate goals. The classic paradigms of vaccinology have proven incapable of producing a viable vaccine due to the complexity of the virus&#8217; replication cycle, its genetic diversity, and a lack of understanding of the immune correlates of protection. Here, we briefly discuss recent vaccine approaches and the immune correlates of protection from HIV-1 infection with a focus on the role of the germinal center as a reservoir of replication-competent virus and its role in the development of broadly neutralizing antibodies in response to vaccination.</p></abstract><kwd-group><kwd>Germinal center</kwd><kwd>T<sub>FH</sub></kwd><kwd>HIV-1</kwd><kwd>vaccines</kwd><kwd>broadly neutralizing antibody</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section1-1179555717695548"><title>Introduction</title><p>AIDS first surfaced in the human population as an outbreak of <italic toggle="yes">Pneumocystis carinii</italic> pneumonia among homosexual men in the United States.<sup><xref rid="bibr1-1179555717695548" ref-type="bibr">1</xref><xref rid="bibr2-1179555717695548" ref-type="bibr"/>-<xref rid="bibr3-1179555717695548" ref-type="bibr">3</xref></sup> It is thought to have been circulating undiscovered in Africa for many years prior. The causative agent is a Baltimore class VI retrovirus, called human immunodeficiency virus 1 (HIV-1). The virus is spread by direct sexual contact, through intravenous delivery of blood or blood products, and through vertical transmission from mother to child. The primary mode of transmission is sexual and infection is typically initiated at mucosal sites (<xref ref-type="fig" rid="fig1-1179555717695548">Figure 1</xref>). As the virus replicates within host cells, it inserts a copy of its genome into that of the host&#8212;a copy that is reproduced every time that cell divides and is capable of reactivation at any time&#8212;a phenomenon called latency. The World Health Organization estimates that 75 million people have been infected since the summer of 1981, and approximately 36 million lives have been lost to the disease. Today, 0.8% of all adults aged between 15 and 50 years are living with HIV.</p><fig id="fig1-1179555717695548" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Mucosal pathogenesis of human immunodeficiency virus 1 (HIV-1). Most of the HIV-1 infections occur at mucosal sites via sexual transmission. On gaining access to tissue-resident CD4<sup>+</sup> T cells or when taken up by tissue-resident dendritic cells (DC), infected cells may be phagocytosed by granulocytes, such as macrophages (M&#981;), and the virus is carried to the draining lymph nodes (DLNs) where these antigen-presenting cells may directly infect CD4<sup>+</sup> T cells. Replication-competent viruses multiply and establish latency. In this way, the DLNs become the largest tissue reservoir during chronic infection.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_1179555717695548-fig1.jpg"/></fig><p>The alarming statistics of the HIV-1 pandemic have spurred an unprecedented amount of research. Molecular medicine has provided clinicians with an arsenal of drugs that target important aspects of the viral lifecycle in hopes to decrease viral load and transmissibility. However, there is still no vaccine to prevent transmission and no feasible method to cure an HIV-1&#8211;infected individual; thus, preventing infection and removing latent virus are major research goals.</p><p>Recent discoveries have shed light on the nature of the infection and produced clues that could have major implications for a cure. In 2009, the transplant of stem cells lacking the HIV-1 co-receptor, chemokine receptor 5 (CCR5), into an HIV-1&#8211;positive patient resulted in a decrease in HIV-1 RNA to undetectable levels.<sup><xref rid="bibr4-1179555717695548" ref-type="bibr">4</xref></sup> Recently, researchers at Temple University reported the first successful ablation of the HIV-1 proviral genome from latently infected human cells.<sup><xref rid="bibr5-1179555717695548" ref-type="bibr">5</xref></sup> Both these represent huge advancements in HIV research and should be pursued, but at present, there are no feasible treatments for HIV-1&#8211;infected patients in places such as sub-Saharan Africa where rates of infection are the highest.</p><p>Unfortunately, all recent vaccine endeavors have proven unsuccessful. However, these failures have led to clues about the necessary correlates of protection (<xref ref-type="table" rid="table1-1179555717695548">Table 1</xref>). Passive transfer studies have shown that neutralizing antibodies are capable of controlling HIV-1 infection and preventing infection,<sup><xref rid="bibr6-1179555717695548" ref-type="bibr">6</xref><xref rid="bibr7-1179555717695548" ref-type="bibr"/>-<xref rid="bibr8-1179555717695548" ref-type="bibr">8</xref></sup> even though no trials to date have produced neutralizing antibodies.<sup><xref rid="bibr9-1179555717695548" ref-type="bibr">9</xref><xref rid="bibr10-1179555717695548" ref-type="bibr"/><xref rid="bibr11-1179555717695548" ref-type="bibr"/><xref rid="bibr12-1179555717695548" ref-type="bibr"/>-<xref rid="bibr13-1179555717695548" ref-type="bibr">13</xref></sup> These results are disheartening, and solving the &#8220;neutralizing antibody problem&#8221; is the subject of much research. Adenovirus vector&#8211;delivered vaccines have not protected macaques from autologous challenge but have decreased viral loads and protected T lymphocytes, indicating that cell-mediated control of infection is also possible. The recent failures of AIDSVAX<sup><xref rid="bibr11-1179555717695548" ref-type="bibr">11</xref></sup> and Merck Ad5<sup><xref rid="bibr13-1179555717695548" ref-type="bibr">13</xref></sup> vaccines are disappointing but further our understanding of how to effectively prevent infection. It is clear that &#8220;traditional&#8221; vaccinology is unlikely to yield a successful therapeutic or prophylactic vaccine against HIV-1. Here, we discuss the development of anti&#8211;HIV-neutralizing antibodies, the germinal center (GC) response to HIV-1 infection, and the GC response to HIV-1 prophylactic vaccines.</p><table-wrap id="table1-1179555717695548" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Summary of past HIV-1 vaccine clinical trials.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_1179555717695548-table1.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Name<break/>Start date<break/>(Results published)<sup>Ref</sup>:</th><th align="left" rowspan="1" colspan="1">RV144<break/>September 2003<break/>(2009)<sup><xref rid="bibr11-1179555717695548" ref-type="bibr">11</xref></sup><hr/></th><th align="left" rowspan="1" colspan="1">STEP<break/>December 2004<break/>(2008)<sup><xref rid="bibr9-1179555717695548" ref-type="bibr">9</xref></sup><hr/></th><th align="left" rowspan="1" colspan="1">Phambili/HVTN 503<break/>July 2005<break/>(2011)<sup><xref rid="bibr10-1179555717695548" ref-type="bibr">10</xref></sup><hr/></th><th align="left" rowspan="1" colspan="1">VRC DNA: Ad5HVTN 505<break/>June 2009<break/>(2011)<sup><xref rid="bibr13-1179555717695548" ref-type="bibr">13</xref></sup><hr/></th></tr><tr><th align="left" rowspan="1" colspan="1">ALVAC-HIV:AIDSVAX B/E (RV144)</th><th align="left" rowspan="1" colspan="1">HVTN 502/504</th><th align="left" rowspan="1" colspan="1">HVTN 503</th><th align="left" rowspan="1" colspan="1">VRC DNA: HVTN 505</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Composition</td><td rowspan="1" colspan="1">Canarypox-HIV gag/pol/env + recombinant gp120 boost</td><td rowspan="1" colspan="1">3 adenovirus serotype 5 vectors encoding HIV-1 gag, pol, and nef</td><td rowspan="1" colspan="1">3 adenovirus serotype 5 vectors encoding HIV-1 gag, pol, and nef</td><td rowspan="1" colspan="1">HIV clade B gag, pol and nef, and EnvA, EnvB, and EnvC plasmids (6)<break/>4 adenovirus serotype 5 vectors encoding clade B gag-pol fusion and env protein from clades A, B, and C</td></tr><tr><td rowspan="1" colspan="1">Regimen</td><td rowspan="1" colspan="1">4 ALVAC-HIV injections at 0, 4, 12, and 24 wk plus boosting with AIDSVAX B/E at weeks 12 and 24</td><td rowspan="1" colspan="1">3 (0, 4, 26 wk), 1 mL injections of 1.5 &#215; 10<sup>10</sup> genome equivalents</td><td rowspan="1" colspan="1">3 (0, 4, 26 wk), 1 mL injections of 1.5 &#215; 10<sup>10</sup> genome equivalents</td><td rowspan="1" colspan="1">3 (0, 4, 8 wk) Biojector injections of 4 mg of each plasmid plus boosting with 10<sup>10</sup> particle units of rAd5 at week 24</td></tr><tr><td rowspan="1" colspan="1">Efficacy</td><td rowspan="1" colspan="1">26.4%&#8211;31%</td><td rowspan="1" colspan="1">&#8722;20%</td><td rowspan="1" colspan="1">&#8722;31%</td><td rowspan="1" colspan="1">&#8722;25%</td></tr><tr><td rowspan="1" colspan="1">Location</td><td rowspan="1" colspan="1">Thailand</td><td rowspan="1" colspan="1">North and South America, Caribbean, and Australia (clade matched)</td><td rowspan="1" colspan="1">South Africa (clade mismatched)</td><td rowspan="1" colspan="1">United States</td></tr><tr><td rowspan="1" colspan="1">Affiliations</td><td rowspan="1" colspan="1">VaxGen (Genentech), Aventis Pasteur</td><td rowspan="1" colspan="1">Merck, HVTN, NIAID/NIH</td><td rowspan="1" colspan="1">Merck, HVTN, NIAID/NIH</td><td rowspan="1" colspan="1">Merck, HVTN, NIAID/NIH</td></tr><tr><td rowspan="1" colspan="1">Key findings</td><td rowspan="1" colspan="1">V1V2 antibodies contribute to protection, and increased env-specific IgA may inhibit protective antibodies</td><td colspan="2" rowspan="1">Preexisting immunity to the adenovirus vector inhibits vaccine efficacy</td><td rowspan="1" colspan="1">Natural B-cell clones expressing potential bNAbs are likely deleted during clonal selection due to autoreactivity</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-1179555717695548"><p>Abbreviations: HIV-1, human immunodeficiency virus 1; NIAID, National Institute of Allergy and Infectious Diseases; NIH, National Institutes of Health.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section2-1179555717695548"><title>B Cells and Neutralizing Antibodies</title><p>B lymphocytes bind antigen via a membrane-bound B-cell receptor (BCR), and they also secrete soluble forms of the BCR that can bind antigen, called antibodies. The envelope (env) protein of HIV-1 is absolutely critical for viral entry and subsequent replication; thus, antibodies that prevent env-mediated binding and entry are protective. When it was first evidenced that serum samples from some elite HIV-1 controlling patients not undergoing antiretroviral treatment could neutralize a spectrum of HIV-1 viruses,<sup><xref rid="bibr14-1179555717695548" ref-type="bibr">14</xref><xref rid="bibr15-1179555717695548" ref-type="bibr"/>-<xref rid="bibr16-1179555717695548" ref-type="bibr">16</xref></sup> researchers grew optimistic that similar broadly neutralizing antibody (bNAb) responses could be elicited by vaccination. In fact, experiments with nonhuman primates (NHPs), as well as analyses from human elite controllers or elite neutralizers, indicate that the presence of neutralizing antibodies correlates with protection from infection.<sup><xref rid="bibr17-1179555717695548" ref-type="bibr">17</xref><xref rid="bibr18-1179555717695548" ref-type="bibr"/>-<xref rid="bibr19-1179555717695548" ref-type="bibr">19</xref></sup> Unfortunately, these antibody responses are not typical. In general, these antibodies target conserved but less-immunogenic epitopes of the env protein or the CD4-binding site (CD4bs), whereas most of the natural responses target less well-conserved epitopes. Broadly neutralizing antibodies also tend to share unique features such as polyreactivity, a large variable heavy-chain complementarity-determining region (HCDR3), and evidence of large amounts of somatic hypermutation. In a cross-sectional study of serum samples from more than 200 patients, Hraber et al<sup><xref rid="bibr20-1179555717695548" ref-type="bibr">20</xref></sup> found that most serum displayed some degree of cross-neutralization and that half of the samples were broadly neutralizing, but with titers at or below the thresholds thought to be protective in NHPs.<sup><xref rid="bibr21-1179555717695548" ref-type="bibr">21</xref></sup> This indicates that most chronically infected patients develop some form of neutralizing antibody but that bNAbs are less common, and thus, although it may be feasible to induce production of neutralizing antibodies, production of antibodies that are cross-reactive but have a more restricted breadth is likely to be more feasible. Some neutralizing epitopes, such as those in the membrane-proximal external region (MPER), or the variable loops on gp41 remain hidden during infection and are generally poorly immunogenic; thus, finding ways to expose these epitopes is critical to the development of protein antigens that will incite the production of neutralizing antibodies. Novel virucides, such as the peptide triazole-thiols that cause lysis of the HIV-1 virion, present the possibility of creating novel antigens for immunization.<sup><xref rid="bibr22-1179555717695548" ref-type="bibr">22</xref><xref rid="bibr23-1179555717695548" ref-type="bibr"/>-<xref rid="bibr24-1179555717695548" ref-type="bibr">24</xref></sup> The development of stable, soluble trimeric forms of env with native-like confirmations<sup><xref rid="bibr25-1179555717695548" ref-type="bibr">25</xref></sup> has renewed interest in the generation of neutralizing antibody with protein vaccination.<sup><xref rid="bibr26-1179555717695548" ref-type="bibr">26</xref></sup></p><p>When designing an immunogen intended to produce neutralizing antibody, it is important to first consider B-cell ontology. B cells develop in the bone marrow and must pass a tolerance checkpoint intended to prevent self-reactive B cells from entering peripheral circulation. It is estimated that approximately 70% of the B cells produced in the bone marrow die there due to self-reactivity.<sup><xref rid="bibr27-1179555717695548" ref-type="bibr">27</xref></sup> Mature B cells that survive in the periphery are still not completely self-tolerant, and it is estimated that nearly 20% of these are self-reactive.<sup><xref rid="bibr28-1179555717695548" ref-type="bibr">28</xref></sup> What this means for the development of vaccine immunogens is that the repertoire of BCRs that could respond to an immunogen is much smaller than the total number of BCRs that could be generated from the germ line. If tolerance reduces the affinity of the BCR or the number of available BCRs, this inhibits the ability of the host to mount an adequate humoral response. bNAb 2F5, which binds to the MPER of gp41, is a prime example of an atypical HIV-neutralizing antibody. 2F5 knock-in mice carrying the human heavy-chain variable (V), diversity (D), and joining (J) regions of human 2F5<sup><xref rid="bibr29-1179555717695548" ref-type="bibr">29</xref></sup> have normal pre&#8211;B-cell development but are lacking in their ability to produce immature B cells, suggesting tolerance-induced killing of these cells at this stage of B-cell development.<sup><xref rid="bibr30-1179555717695548" ref-type="bibr">30</xref></sup> This was later verified by the discovery that the MPER epitope bound by 2F5 (ELDKWA) is present in both the mouse and the human kynureninase enzyme.<sup><xref rid="bibr31-1179555717695548" ref-type="bibr">31</xref>,<xref rid="bibr32-1179555717695548" ref-type="bibr">32</xref></sup></p><p>With B-cell ontology in mind, research has shifted to developing immunogens that will induce a particular B-cell lineage. When a na&#239;ve B cell encounters an antigen, it recognizes it via the BCR but also undergoes affinity maturation and somatic hypermutation as the humoral response continues to evolve such that the antibodies isolated later in an infection have much higher affinity for their antigen, that is to say, the quality of the B-cell response increases with increasing exposure to the antigen. It is also important to note that HIV rapidly mutates to escape immune pressures encountered in the host such that a constant arms-race occurs inside an infected patient, and usually the B-cell response is outpaced by viral mutagenesis. This is the reason why bNAbs are typically isolated after years of chronic infection.<sup><xref rid="bibr33-1179555717695548" ref-type="bibr">33</xref></sup> Awareness of this phenomenon has led to the idea of designing a &#8220;reverse antigen.&#8221; This approach involves isolating a set of clonally related B cells that neutralize HIV-1 and using computational approaches to determine the original or intermediate antibodies that the neutralizing antibodies would have likely developed from during maturation of the humoral response, and designing an antigen that will be recognized by these early antibodies, thus allowing the immune system to mature until neutralizing antibodies are produced.<sup><xref rid="bibr34-1179555717695548" ref-type="bibr">34</xref></sup> Jardine and colleagues<sup><xref rid="bibr35-1179555717695548" ref-type="bibr">35</xref></sup> used this approach to design a gp120 mimetic that was capable of stimulating germ line BCRs and was indeed recognized by the VRC01 class of patient-isolated bNAbs, validating the approach. It has recently been demonstrated that multiple B-cell lineages may cooperate to produce bNAbs,<sup><xref rid="bibr36-1179555717695548" ref-type="bibr">36</xref></sup> indicating that a multipronged approach to this technique is likely necessary. Similarly, in a landmark study, Wu and colleagues demonstrated that over a 15-year period, the mutational rate of antibodies in long-lived plasma cell lineages correlates with the mutational rate of HIV-1 quasispecies and that this high mutational rate leads to the development of the extraordinary antibodies isolated from latently infected patients.<sup><xref rid="bibr37-1179555717695548" ref-type="bibr">37</xref></sup> Finally, McGuire and colleagues developed a modified env immunogen in which certain variable regions of the protein have been removed and demonstrated that this modified env was capable of eliciting germ line&#8211;reverted bNAbs as opposed to nonneutralizing antibodies.<sup><xref rid="bibr38-1179555717695548" ref-type="bibr">38</xref></sup> These studies indicate that rational immunogen design might be used to generate HIV-1 immunogens that specifically result in the production of neutralizing antibodies.</p><p>Neutralization is not the only mechanism of antibody-mediated protection (<xref ref-type="fig" rid="fig2-1179555717695548">Figure 2</xref>). Antibodies also function to induce antibody-dependent cell-mediated cytotoxicity (ADCC). Natural killer (NK) cells mediate classical ADCC by binding to the Fc region of an antibody bound to a cell that expresses viral proteins on its surface. Engagement of the NK-cell Fc receptor leads to release of cytotoxic cytokines that induce apoptosis in the target cell. Studies have shown that early ADCC responses to HIV env proteins can control viremia.<sup><xref rid="bibr39-1179555717695548" ref-type="bibr">39</xref></sup> Interestingly, it has also been shown that the specificity of the antibodies mediating ADCC differs between HIV controllers and noncontrollers, whereas the functionality of their NK cells remains the same with HIV controllers more often producing env-targeted antibodies.<sup><xref rid="bibr40-1179555717695548" ref-type="bibr">40</xref></sup> Antibodies can also mediate phagocytosis, complement activation, and mucus entrapment.<sup><xref rid="bibr41-1179555717695548" ref-type="bibr">41</xref><xref rid="bibr42-1179555717695548" ref-type="bibr"/>-<xref rid="bibr43-1179555717695548" ref-type="bibr">43</xref></sup> In attempts to cure chronic HIV-1 infection, nonclassical HIV immunogens, such as those targeting the transactivator (Tat), have been developed. Indeed, it has been shown that antibodies targeting Tat are capable of preventing HIV reactivation and limiting pathogenesis.<sup><xref rid="bibr44-1179555717695548" ref-type="bibr">44</xref></sup></p><fig id="fig2-1179555717695548" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Role of antibodies in HIV-1 infection. Affinity-matured, class-switched, highly-mutated, long-lived plasma cells can secrete anti&#8211;HIV-neutralizing antibodies that are capable of neutralizing free virus to prevent infection of target cells (left) as well as mediating ADCC or ADCP (middle) by natural killer cells. Quiescent cells that are latently infected remain immune to anti-HIV responses (right). ADCC indicates antibody-dependent cell-mediated cytotoxicity; ADCP, antibody-dependent cellular phagocytosis; HIV-1, human immunodeficiency virus 1; NK, natural killer.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_1179555717695548-fig2.jpg"/></fig><p>Although production of bNAb is important to prevent primary HIV-1 infection, it is important to note that the quality of antibody produced as a result of infection or vaccination is greatly enhanced by optimal help from the cell-mediated arm of the immune system. B cells that are activated independently of CD4<sup>+</sup> helper T cells produce polyclonal antibodies. However, GC formation and the processes of affinity maturation and isotype switching of antibodies can only occur with the help of T cells. The goal of vaccination would be to prime recipients and induce a memory response that is protective against subsequent HIV-1 challenge, but memory B cells are formed only in GCs. For this reason, it is unlikely that a vaccine platform that solely elicits a B-cell response will provide long-lived immunity. Protein antigens are highly immunogenic and elicit primarily an antibody-mediated response, which may help neutralize infectious viral particles initially but will likely not lead to a robust recall response; thus, a combination of platforms is a better option.</p><p>With current data indicating that the traditional approach to vaccine development is likely to be ineffective against HIV, researchers have developed unique antigens and antigen delivery systems. The use of adenovirus and adeno-associated virus (AAV) serotypes to deliver HIV antigens proved a promising way to achieve long-lasting expression of antigens<sup><xref rid="bibr45-1179555717695548" ref-type="bibr">45</xref><xref rid="bibr46-1179555717695548" ref-type="bibr"/>-<xref rid="bibr47-1179555717695548" ref-type="bibr">47</xref></sup> but can be hindered by the presence of preexisting host immunity against the vector.<sup><xref rid="bibr48-1179555717695548" ref-type="bibr">48</xref>,<xref rid="bibr49-1179555717695548" ref-type="bibr">49</xref></sup> As the most conserved regions of the envelope protein are the CD4- and co-receptor-binding sites, recombinant fusion proteins targeting these epitopes provide a nontraditional means of controlling or preventing HIV infections.<sup><xref rid="bibr50-1179555717695548" ref-type="bibr">50</xref><xref rid="bibr51-1179555717695548" ref-type="bibr"/>-<xref rid="bibr52-1179555717695548" ref-type="bibr">52</xref></sup> Interestingly, AAV vectors have been used as a gene therapy vehicle to deliver these molecules.<sup><xref rid="bibr50-1179555717695548" ref-type="bibr">50</xref></sup> In the most promising of these approaches, the coding sequence of eCD4-Ig, a recombinant immunoadhesin form of CD4 (CD4-Ig), and CCR5mim1, a CCR5 mimetic peptide derived from bNAb E51, were delivered to rhesus macaque via intramuscular injection of AAV. Gardner and colleagues demonstrate that eCD4-Ig bound and neutralized most of the HIV-1 isolates better than either of the components alone and was also capable of neutralizing simian/human immunodeficiency virus (SHIV) isolates. The group also demonstrated stable expression of the construct up to 40 weeks post inoculation in rhesus macaques and protection against challenge with a variety of SHIVs.<sup><xref rid="bibr53-1179555717695548" ref-type="bibr">53</xref></sup> Other promising vectors include modified cytomegalovirus<sup><xref rid="bibr54-1179555717695548" ref-type="bibr">54</xref></sup> and adenovirus serotype 26 (Ad26) which may avoid the issue of preexisting immunity that hinders other serotypes.<sup><xref rid="bibr55-1179555717695548" ref-type="bibr">55</xref></sup></p></sec><sec id="section3-1179555717695548"><title>The GC in HIV-1 Infection</title><p>It is important to note that the germinal center reaction (GCR) occurs in the presence of HIV-1 virions. Dendritic cells are known to carry immune complexes containing HIV-1 virions on their processes to the GC, and follicular helper T (T<sub>FH</sub>) cells are CD4<sup>+</sup> and thus targets for HIV-1 infection. Despite this, HIV-1&#8211;infected patients have higher numbers of T<sub>FH</sub> cells and GC B cells,<sup><xref rid="bibr56-1179555717695548" ref-type="bibr">56</xref>,<xref rid="bibr57-1179555717695548" ref-type="bibr">57</xref></sup> leading to increased numbers of circulating B cells, hypergammaglobulinemia, and, in some cases, B-cell lymphomas.<sup><xref rid="bibr58-1179555717695548" ref-type="bibr">58</xref></sup> It is well established that CD4<sup>+</sup> T cells in the lymph nodes serve as reservoirs for HIV-1.<sup><xref rid="bibr57-1179555717695548" ref-type="bibr">57</xref>,<xref rid="bibr59-1179555717695548" ref-type="bibr">59</xref>,<xref rid="bibr60-1179555717695548" ref-type="bibr">60</xref></sup> Recently, Kohler et al<sup><xref rid="bibr61-1179555717695548" ref-type="bibr">61</xref></sup> used spinoculation of human tonsillar cells to demonstrate that GC T<sub>FH</sub> are highly permissive to HIV infection, more so than extrafollicular or non-GC T<sub>FH</sub> which express low levels of programmed death 1 (PD-1) and C-X-C chemokine receptor 5 (CXCR5). They further demonstrated, by in situ hybridization, the presence of increased HIV-1 RNA in the GCs compared with the extrafollicular areas in sections of inguinal lymph node biopsies from HIV-1&#8211;positive, treatment-na&#239;ve, non-AIDS patients. It is also well established that T<sub>FH</sub> from HIV-positive patients provide inadequate help to B cells in vitro,<sup><xref rid="bibr62-1179555717695548" ref-type="bibr">62</xref></sup> but the underlying cause of this impairment has not been definitively determined. Using a unique cohort of organ transplant patients or patients requiring splenectomy, Colineau et al attempted to elucidate the underlying causes of this impairment. The group determined that there was an increase in GC T<sub>FH</sub> in HIV-positive patients but that these cells had decreased messenger RNA (mRNA) expression of CD40L, OX40, and inducible costimulator (ICOS)&#8212;molecules involved in T<sub>FH</sub> stimulation.<sup><xref rid="bibr63-1179555717695548" ref-type="bibr">63</xref></sup> Interestingly, although these cells had decreased mRNA levels of STAT3, a master signal transducer required for maintenance of the T<sub>FH</sub> phenotype, they did not have decreased Bcl6 expression compared with HIV-1&#8211;negative cells. Despite this, the number of follicular regulatory T (T<sub>FR</sub>) cells in HIV-1&#8211;positive spleens increased, indicative of continued GC reactions which correlate with the increased numbers of T<sub>FH</sub> and B cells observed in HIV patients.<sup><xref rid="bibr63-1179555717695548" ref-type="bibr">63</xref></sup> Understanding the source of the defect in T<sub>FH</sub> help during HIV-1 infection is imperative to the development of an HIV cure.</p><p>Although it is evident that lymph node GC T<sub>FH</sub> cells are major reservoirs of HIV-1 virus in chronically infected patients,<sup><xref rid="bibr59-1179555717695548" ref-type="bibr">59</xref></sup> it appears that this location is somehow protected from CD8<sup>+</sup> T-cell immune surveillance. There is evidence that the acute increase in CD8<sup>+</sup> T cells coincides with a decrease in viremia,<sup><xref rid="bibr64-1179555717695548" ref-type="bibr">64</xref></sup> supporting the notion that CD8<sup>+</sup> T-cell responses can mediate clearance of infected cells. Access to lymph node GCs is dependent on the CXCR5/CXCL13 axis. CXCR5<sup>+</sup> CD8<sup>+</sup> T cells have been shown to localize to the B-cell follicle and even exhibit a regulatory function, at least in the context of B-cell lymphoma.<sup><xref rid="bibr65-1179555717695548" ref-type="bibr">65</xref></sup> Recently, CXCR5<sup>+</sup>CD44<sup>hi</sup>CD8<sup>+</sup> T cells with regulatory activity (secretion of interleukin [IL]-10) have been demonstrated to limit HIV replication in T<sub>FH</sub>, impair IL-21 production, and inhibit IgG secretion during ex vivo HIV infection, indicating a unique CD8<sup>+</sup> regulatory component of GCs during HIV infection.<sup><xref rid="bibr66-1179555717695548" ref-type="bibr">66</xref></sup> Further studies are needed to characterize the access of CD8<sup>+</sup> T cells to the GC and to evaluate whether these cells could kill HIV-1&#8211;infected T<sub>FH</sub> cells therein.</p></sec><sec id="section4-1179555717695548"><title>The GC and Vaccine-Induced Responses</title><p>Germinal centers are dynamic sites within lymphoid organs where mature B cells undergo somatic hypermutation, affinity maturation, and class-switch recombination of the BCR. The outcome of the GCR is that these mature B cells differentiate into long-lived plasma cells and memory B cells, the cells responsible for instituting humoral immunologic memory (<xref ref-type="fig" rid="fig3-1179555717695548">Figure 3</xref>). Humoral memory is the hallmark of successful vaccination and memory B cells mediate this memory; therefore, optimizing the GC response to HIV-1 vaccine antigens is integral to the development of effective HIV prophylactics.</p><fig id="fig3-1179555717695548" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>The germinal center reaction. On antigen presentation in the context of the proper cytokine milieu, na&#239;ve CD4<sup>+</sup> T cells differentiate into follicular helper T (T<sub>FH</sub>) cells and migrate to germinal centers where they select germinal center B cells (GC B) which are responsive to the appropriate antigen via presentation of the antigen on major histocompatibility complex (MHC I). Both T<sub>FH</sub> and GC B cells traffic to the germinal center by virtue of their expression of the receptor CXCR5, following a chemokine gradient of the CXCR5 ligand CXCL13. T<sub>FH</sub> cells and GC B cells make physical connection between costimulatory molecules, B7 and CD28, CD40 and CD40L, inducible costimulator (ICOS) and ICOS ligand (ICOSL), as well as PD-1 and PD-1L. This interaction is also cytokine based with the T<sub>FH</sub> cell secreting interleukin (IL)-21 which is recognized by the IL-12R on GC B cells and mediates STAT3 support of affinity maturation, somatic hypermutation, and class switching of antibodies. T<sub>FH</sub> cells also secrete IL-4 which is recognized by the IL-4 receptor on GC B cells and supports STAT3 expression. Antigen-specific dendritic cells which also present antigen to T<sub>FH</sub> secrete IL-6 which promotes Bcl-6 expression in T<sub>FH</sub> and GC B supporting the GC phenotype. Finally, this reaction is subject to regulation by T follicular regulatory (T<sub>FR</sub>) cells which secrete IL-10 and inhibit both T<sub>FH</sub> and GC B function.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_1179555717695548-fig3.jpg"/></fig><p>The selection and differentiation of B cells in the GC are mediated by a special subset of CD4<sup>+</sup> T cells called T<sub>FH</sub> cells. Follicular helper T cells differentiate from na&#239;ve CD4<sup>+</sup> T cells when antigen is presented to them by antigen-presenting cells that secrete the necessary cytokine milieu, namely, the cytokines IL-21,<sup><xref rid="bibr67-1179555717695548" ref-type="bibr">67</xref></sup> IL-6,<sup><xref rid="bibr68-1179555717695548" ref-type="bibr">68</xref></sup> and IL-12.<sup><xref rid="bibr69-1179555717695548" ref-type="bibr">69</xref></sup> After acquiring the T<sub>FH</sub> phenotype, these cells migrate to the GC by virtue of their expression of CXCR5 following a gradient of the ligand for CXCR5, C-X-C ligand 13 (CXCL13).<sup><xref rid="bibr70-1179555717695548" ref-type="bibr">70</xref>,<xref rid="bibr71-1179555717695548" ref-type="bibr">71</xref></sup> In the GC, T<sub>FH</sub> cells interact both physically and via cytokine signaling with GC B cells. The physical interaction between GC B cells and T<sub>FH</sub> includes ICOS on T<sub>FH</sub> and its ligand ICOSL, PD-1<sup><xref rid="bibr72-1179555717695548" ref-type="bibr">72</xref></sup> and its ligand PD-L1,<sup><xref rid="bibr73-1179555717695548" ref-type="bibr">73</xref></sup> CD80/CD86,<sup><xref rid="bibr74-1179555717695548" ref-type="bibr">74</xref></sup> and CD40/CD40L.<sup><xref rid="bibr75-1179555717695548" ref-type="bibr">75</xref></sup> Follicular helper T cells signal GC B-cell differentiation into memory B cells and long-lived plasma cells by secreting IL-4 and IL-21.<sup><xref rid="bibr76-1179555717695548" ref-type="bibr">76</xref><xref rid="bibr77-1179555717695548" ref-type="bibr"/>-<xref rid="bibr78-1179555717695548" ref-type="bibr">78</xref></sup> Follicular helper T cells are typically identified by the expression of CXCR5, CD4, PD-1, and the transcription factor Bcl-6. It has been shown that PD-1 signaling through PD-L1 is essential for the development of plasma cells and that deficiency in PD-1 signaling leads to a decrease in the number of long-lived plasma cells.<sup><xref rid="bibr79-1179555717695548" ref-type="bibr">79</xref></sup></p><p>As the GCR is critical to the development of humoral immunity and immune memory, studying this response is critical to the development of vaccines targeting pathogens. Unfortunately, direct examination of the GC response in human patients is rarely feasible. CD4<sup>+</sup> cells possessing T<sub>FH</sub>-like phenotype (CXCR5<sup>+</sup> PD-1<sup>+</sup>) cells can be isolated from the periphery, and it has been demonstrated that an early preservation of B and T cells with this phenotype predicts a broad neutralizing antibody response in HIV-1 chronically infected patients.<sup><xref rid="bibr80-1179555717695548" ref-type="bibr">80</xref>,<xref rid="bibr81-1179555717695548" ref-type="bibr">81</xref></sup> These peripheral T<sub>FH</sub>-like cells have also been connected to the ability to develop an effective humoral response to vaccination.<sup><xref rid="bibr82-1179555717695548" ref-type="bibr">82</xref></sup> He et al<sup><xref rid="bibr83-1179555717695548" ref-type="bibr">83</xref></sup> reported that a population of CCR7<sup>lo</sup>PD-1<sup>Hi</sup>CXCR<sup>+</sup> T cells correlated with the formation of GCs in both humans and mice, whereas a CCR7<sup>Hi</sup>PD-1<sup>Lo</sup>CXCR5<sup>+</sup> CD4<sup>+</sup> T cell possessed a resting, memory-like phenotype and could not be used as a biomarker for GC activity. In another study, conflicting results were observed; when measuring CCR7<sup>Hi</sup>CXCR5<sup>+</sup>PD-1<sup>Hi</sup> cells in the periphery T<sub>FH</sub> (pT<sub>FH</sub>) cells, Boswell et al<sup><xref rid="bibr84-1179555717695548" ref-type="bibr">84</xref></sup> report no relationship between serum-neutralizing capability and pT<sub>FH</sub> cells, env-specific antibody, or total plasma immunoglobulin levels even though these cells were capable of in vitro B-cell help, concluding that these cells possess a memory-like phenotype as opposed to a classical GC T<sub>FH</sub> phenotype. These conflicting results indicate that another measure of the GCR is necessary to gauge vaccine-induced responses. Recently, Havenar-Daughton et al<sup><xref rid="bibr85-1179555717695548" ref-type="bibr">85</xref></sup> reported the use of soluble CXCL13, the chemokine that attracts T<sub>FH</sub> and GC B cells to lymph node GCs, in blood as a biomarker for GC activity. The group reported that elevated CXCL13 levels correlated with the development of anti&#8211;HIV-1 bNAbs in the well-characterized International AIDS Vaccine Initiative protocol C cohort,<sup><xref rid="bibr82-1179555717695548" ref-type="bibr">82</xref>,<xref rid="bibr86-1179555717695548" ref-type="bibr">86</xref></sup> as well as in immunized mice and macaques.<sup><xref rid="bibr85-1179555717695548" ref-type="bibr">85</xref></sup> Measurement of soluble CXCL13 could provide a feasible means of evaluating HIV-1 vaccine&#8211;induced responses as well as a clinical correlate of HIV infection in the lymph node. Recently, this same group correlated the development of tier 2 HIV-neutralizing antibodies post env trimer immunization with GC B-cell and T<sub>FH</sub>-cell frequencies in a rhesus macaque model using longitudinal fine-needle aspiration.<sup><xref rid="bibr87-1179555717695548" ref-type="bibr">87</xref></sup></p><p>Finally, inciting a robust GC response to vaccine antigens would mean seeding an antigen-experienced memory cell pool. As T<sub>FH</sub> select B cells with the appropriate affinity and support their differentiation into long-lived plasma cells and memory B cells, a vaccine that promotes the induction of T<sub>FH</sub> cells and GCs is likely to induce immunologic memory with fewer immunizations. Although the precise kinetics of memory B-cell formation post antigen exposure are under debate,<sup><xref rid="bibr88-1179555717695548" ref-type="bibr">88</xref></sup> it is still widely held that the generation of memory B and plasma cells following exposure to T-dependent antigens depends on the GCR. The T<sub>FH</sub> phenotype is promoted by signaling through ILs 12, 6, and 21. It has recently been demonstrated that the oil-in-water formulated adjuvant MF59, which has been shown to induce broad, potent, protective humoral responses to influenza vaccination, mediates its adjuvant effect by enhancing T<sub>FH</sub> cells in early and adult life.<sup><xref rid="bibr89-1179555717695548" ref-type="bibr">89</xref>,<xref rid="bibr90-1179555717695548" ref-type="bibr">90</xref></sup> Interestingly, it was also reported that this T<sub>FH</sub> enhancement observed in young adult and adult mice is absent in 1-week-old neonatal mice due to an increased number of T<sub>FR</sub> cells which suppress the GCR.<sup><xref rid="bibr89-1179555717695548" ref-type="bibr">89</xref></sup> A recent study undertaken to evaluate the benefit of using MF59 instead of alum in the ALVAC vaccine formulation discovered that although MF59 has been shown to enhance GC formation, it did not lead to increased protection from challenge in an SHIV model.<sup><xref rid="bibr91-1179555717695548" ref-type="bibr">91</xref></sup> The plasticity of CD4<sup>+</sup> T cells provides another potential avenue for augmenting the GC response. It has been shown that T<sub>H</sub>17 cells preferentially differentiate into T<sub>FH</sub> cells in the mucosa and that this plasticity is causally linked to IgA production in the gut.<sup><xref rid="bibr92-1179555717695548" ref-type="bibr">92</xref>,<xref rid="bibr93-1179555717695548" ref-type="bibr">93</xref></sup> IgA production has been linked to protection against HIV-1 infection.<sup><xref rid="bibr94-1179555717695548" ref-type="bibr">94</xref><xref rid="bibr95-1179555717695548" ref-type="bibr"/>-<xref rid="bibr96-1179555717695548" ref-type="bibr">96</xref></sup> This could mean that T<sub>H</sub>17 cells are an, as yet, unexplored means of enhancing the GC response and increasing vaccine-induced IgA production in the mucosa, which is the primary site of HIV-1 transmission. DNA vaccines incorporating plasmid-encoded IL-12 have demonstrated the ability to enhance humoral responses to HIV-1 DNA vaccines.<sup><xref rid="bibr97-1179555717695548" ref-type="bibr">97</xref><xref rid="bibr98-1179555717695548" ref-type="bibr"/>-<xref rid="bibr99-1179555717695548" ref-type="bibr">99</xref></sup> This humoral enhancement is partially linked to increased GC responses induced when IL-12 is included as a molecular cytokine adjuvant (Gary and Kutzler, unpublished results). Interleukin 12 is thought to mediate this effect via STAT4 which supports Bcl-6 expression which promotes and maintains the T<sub>FH</sub> and GC B phenotype.<sup><xref rid="bibr69-1179555717695548" ref-type="bibr">69</xref></sup> Notably, a defect in IL-12 signaling interferes with T<sub>FH</sub> cell function in vivo.<sup><xref rid="bibr100-1179555717695548" ref-type="bibr">100</xref></sup> The delivery of malaria antigens formulated with nanoparticle-based delivery was recently demonstrated to enhance GC formation and T<sub>FH</sub> expansion compared with the adjuvant monophosphoryl lipid A.<sup><xref rid="bibr101-1179555717695548" ref-type="bibr">101</xref></sup> The inclusion of ligands that bind the retinoic acid&#8211;inducible gene-I pattern recognition receptor pathway, such as synthetic double-stranded RNA (dsRNA), has also been shown to enhance the GC response to influenza antigens.<sup><xref rid="bibr102-1179555717695548" ref-type="bibr">102</xref></sup> Adenosine deaminase, a member of the growth factor cytokine family, has been demonstrated to enhance the costimulatory effect of DCs on CD4<sup>+</sup> T cells<sup><xref rid="bibr103-1179555717695548" ref-type="bibr">103</xref></sup> and has been shown to enhance T-cell responses elicited by DCs loaded with inactivated HIV viruses.<sup><xref rid="bibr104-1179555717695548" ref-type="bibr">104</xref></sup></p><p>The discovery of adjuvants or vaccine platforms that enhance the GC response is integral to the development of vaccines with shorter immunization courses (<xref ref-type="table" rid="table2-1179555717695548">Table 2</xref>). Inciting a robust GC response and seeding the memory B-cell pool following a single immunization will mean fewer immunizations, leading to dose sparing and reduced production costs, all important for delivering vaccines to the developing world. The development of reliable biomarkers to gauge the GCR will be critical to evaluate the efficacy of vaccines and adjuvants targeting this reaction.</p><table-wrap id="table2-1179555717695548" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Summary of vaccine adjuvants targeting the germinal center reaction.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_1179555717695548-table2.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Adjuvant</th><th align="left" rowspan="1" colspan="1">Formulation/delivery</th><th align="left" rowspan="1" colspan="1">Antigen</th><th align="left" rowspan="1" colspan="1">Target</th><th align="left" rowspan="1" colspan="1">Receptor</th><th align="left" rowspan="1" colspan="1">Mechanism</th><th align="left" rowspan="1" colspan="1">Citation</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Chemical</td><td rowspan="1" colspan="1">MF59</td><td rowspan="1" colspan="1">Squalene oil, Tween-8, Span-85</td><td rowspan="1" colspan="1">Influenza</td><td rowspan="1" colspan="1">DCs</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">Promotes DC migration, Ag uptake, and Ag presentation in DLNs</td><td rowspan="1" colspan="1">Gavillet et al<sup><xref rid="bibr89-1179555717695548" ref-type="bibr">89</xref></sup> and Lofano et al<sup><xref rid="bibr90-1179555717695548" ref-type="bibr">90</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Biological</td><td rowspan="1" colspan="1">Lipid-based nanoparticles</td><td rowspan="1" colspan="1">Lipid bilayers, encapsulating Ag or adjuvant; displaying Ag on surface</td><td rowspan="1" colspan="1">Malaria</td><td rowspan="1" colspan="1">APCs</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">Unknown&#8212;increased T<sub>FH</sub> numbers</td><td rowspan="1" colspan="1">Moon et al<sup><xref rid="bibr101-1179555717695548" ref-type="bibr">101</xref></sup></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">RIG-I agonists</td><td rowspan="1" colspan="1">5-PPP (dsRNA) or similar RIG-I ligands</td><td rowspan="1" colspan="1">Influenza</td><td rowspan="1" colspan="1">APCs (hypothesized)</td><td rowspan="1" colspan="1">RIG-I</td><td rowspan="1" colspan="1">Unknown&#8212;enhancement in GC B and T<sub>FH</sub> numbers; increased plasma and memory B-cell formation</td><td rowspan="1" colspan="1">Moon et al<sup><xref rid="bibr101-1179555717695548" ref-type="bibr">101</xref></sup> and Kulkarni et al<sup><xref rid="bibr102-1179555717695548" ref-type="bibr">102</xref></sup></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Adenosine deaminase</td><td rowspan="1" colspan="1">Recombinant protein, plasmid DNA encoded</td><td rowspan="1" colspan="1">HIV</td><td rowspan="1" colspan="1">DCs, T cells; also B and NK cells</td><td rowspan="1" colspan="1">Binds CD26/DPP-4</td><td rowspan="1" colspan="1">Enhancement of helper T function and activation via costimulation</td><td rowspan="1" colspan="1">Martinez-Navio and colleagues<sup><xref rid="bibr103-1179555717695548" ref-type="bibr">103</xref>,<xref rid="bibr104-1179555717695548" ref-type="bibr">104</xref></sup></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">IL-12</td><td rowspan="1" colspan="1">Recombinant protein, plasmid DNA encoded</td><td rowspan="1" colspan="1">HIV<sup><xref ref-type="table-fn" rid="table-fn3-1179555717695548">a</xref></sup></td><td rowspan="1" colspan="1">CD4 T cells, APCs</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">STAT4-mediated upregulation of Bcl-6</td><td rowspan="1" colspan="1">Ma et al,<sup><xref rid="bibr69-1179555717695548" ref-type="bibr">69</xref></sup> Hirao et al,<sup><xref rid="bibr97-1179555717695548" ref-type="bibr">97</xref></sup> Chong et al,<sup><xref rid="bibr98-1179555717695548" ref-type="bibr">98</xref></sup> Kalams et al,<sup><xref rid="bibr99-1179555717695548" ref-type="bibr">99</xref></sup> and Schmitt et al<sup><xref rid="bibr100-1179555717695548" ref-type="bibr">100</xref></sup></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn2-1179555717695548"><p>Abbreviations: APCs, antigen-presenting cells; DCs, dendritic cells; DLNs, draining lymph nodes; dsRNA, double-stranded RNA; GC, germinal center; HIV, human immunodeficiency virus; IL-12, interleukin 12; NK, natural killer; RIG-I, retinoic acid&#8211;inducible gene-I; T<sub>FH</sub>, follicular helper T.</p></fn><fn id="table-fn3-1179555717695548"><label>a</label><p>Unpublished results.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section5-1179555717695548"><title>Perspectives and Future Challenges</title><p>The AIDS epidemic has been raging for more than 3 decades. Great advancements have been made in treatment, and the life expectancy of an HIV-1&#8211;infected individual approaches that of uninfected individuals. Our ability to drastically decrease the morbidity and mortality associated with chronic infection is impressive; however, 2.5 million people worldwide become infected with HIV-1 each year, that is, more than 6000 people every day. These intimidating statistics inspire continued research aimed at the development of a prophylactic vaccine.</p><p>As immunologic knowledge improves, the ability to create more effective prophylactics increases. In the past 30 years, more has been learned about the types of immune responses elicited by different vaccine platforms since the advent of vaccinology, and this is due in great part to HIV-1 research. Despite this, several obstacles still impede us&#8212;preexisting immunity to HIV vaccine vectors may inhibit the efficacy of vaccine candidates, adequate animal models to accurately predict protection in humans do not exist, and the evolution of the virus in response to host selection pressure cannot be accurately predicted. The following question remains: how do we develop a prophylactic vaccine against HIV-1 that is highly immunogenic in humans? The vaccine needs to elicit a neutralizing antibody response, with high titers of plasma antibodies, as well as a large pool of memory B cells, but this response requires T<sub>FH</sub> cells that are themselves permissive to infection.</p><p>The formulation of such a vaccine remains elusive. Protein-based vaccines generally evoke strong antibody responses, and live vectored vaccines can initiate both arms of the immune response, provided they are not hindered by preexisting immunity. DNA vaccines elicit strong cell-mediated responses and appear capable of engendering an effective T<sub>FH</sub> response, but the recent DNA prime-adenovirus boost human trial did not demonstrate efficacy.<sup><xref rid="bibr13-1179555717695548" ref-type="bibr">13</xref></sup> The only approach to demonstrate efficacy to date was the initial phase 2 trial using a canary pox vector bearing HIV-1 gag, pol, and env proteins, boosted with a recombinant gp120 protein, and still the vaccine proved only 25% effective at preventing infection. The plasticity of CD4<sup>+</sup> T-cell subsets is of particular interest. Recent studies have demonstrated the ability of mucosal resident T<sub>H</sub>17 cells to differentiate into GC T<sub>FH</sub> cells and stimulate mucosal antibody secretion. It may be feasible to target these cells prior to differentiation via vaccination, priming an exceptional GCR.</p><p>The failure of previous vaccine trial has revealed the complex nature of a successful immune response against HIV-1 as well as the types of immune responses engendered by the different platforms available. This makes better assumptions about the outcomes of a trial possible. The prime-boost regimen will likely prove to be the most effective method for prompting both a humoral and a cell-mediated response. This dearth of knowledge has led to creative approaches to solving the HIV-1 pandemic.</p></sec></body><back><fn-group><fn fn-type="other"><p><bold>Peer review:</bold>Six peer reviewers contributed to the peer review report. Reviewers&#8217; reports totaled 1179 words, excluding any confidential comments to the academic editor.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold>The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was partially funded under the Ruth L. Kirschstein National Research Service Award 5T32MH079785 (Rappaport, principal investigator, and Wigdahl, principal investigator of subcontract to Drexel University College of Medicine) as E.G. is a trainee on this grant. The contents of the paper are solely the responsibility of the authors and do not necessarily represent the official views of the national Institutes of Health. This work is also supported by the W.W. Smith Charitable Trust Foundation grant A1404 to M.K.</p></fn><fn fn-type="COI-statement"><p><bold>Declaration of conflicting interests:</bold>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></fn><fn fn-type="other"><p><bold>Author Contributions:</bold> ENG conceptualized and wrote this article with comments and guidance from MAK.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-1179555717695548"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masur</surname><given-names>H</given-names></name><name name-style="western"><surname>Michelis</surname><given-names>MA</given-names></name><name name-style="western"><surname>Greene</surname><given-names>JB</given-names></name><etal/></person-group><article-title>An outbreak of community-acquired <italic toggle="yes">Pneumocystis carinii</italic> pneumonia: initial manifestation of cellular immune dysfunction</article-title>. <source>N Engl J Med</source>. <year>1981</year>;<volume>305</volume>:<fpage>1431</fpage>&#8211;<lpage>1438</lpage>.<pub-id pub-id-type="pmid">6975437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM198112103052402</pub-id></mixed-citation></ref><ref id="bibr2-1179555717695548"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gottlieb</surname><given-names>MS</given-names></name><name name-style="western"><surname>Schanker</surname><given-names>HM</given-names></name><name name-style="western"><surname>Fan</surname><given-names>PT</given-names></name><name name-style="western"><surname>Saxon</surname><given-names>A</given-names></name><name name-style="western"><surname>Weisman</surname><given-names>JD</given-names></name><name name-style="western"><surname>Pozalski</surname><given-names>I.</given-names></name></person-group><article-title><italic toggle="yes">Pneumocystis pneumonia</italic>&#8212;Los Angeles</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>1981</year>;<volume>30</volume>:<fpage>250</fpage>&#8211;<lpage>252</lpage>.<pub-id pub-id-type="pmid">6265753</pub-id></mixed-citation></ref><ref id="bibr3-1179555717695548"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gottlieb</surname><given-names>MS</given-names></name><name name-style="western"><surname>Schroff</surname><given-names>R</given-names></name><name name-style="western"><surname>Schanker</surname><given-names>HM</given-names></name><etal/></person-group><article-title><italic toggle="yes">Pneumocystis carinii</italic> pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency</article-title>. <source>N Engl J Med</source>. <year>1981</year>;<volume>305</volume>:<fpage>1425</fpage>&#8211;<lpage>1431</lpage>.<pub-id pub-id-type="pmid">6272109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM198112103052401</pub-id></mixed-citation></ref><ref id="bibr4-1179555717695548"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#252;tter</surname><given-names>G</given-names></name><name name-style="western"><surname>Nowak</surname><given-names>D</given-names></name><name name-style="western"><surname>Mossner</surname><given-names>M</given-names></name><etal/></person-group><article-title>Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>360</volume>: <fpage>692</fpage>&#8211;<lpage>698</lpage>.<pub-id pub-id-type="pmid">19213682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa0802905</pub-id></mixed-citation></ref><ref id="bibr5-1179555717695548"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>W</given-names></name><name name-style="western"><surname>Kaminski</surname><given-names>R</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F</given-names></name><etal/></person-group><article-title>RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2014</year>;<volume>111</volume>:<fpage>11461</fpage>&#8211;<lpage>11466</lpage>.<pub-id pub-id-type="pmid">25049410</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1405186111</pub-id><pub-id pub-id-type="pmcid">PMC4128125</pub-id></mixed-citation></ref><ref id="bibr6-1179555717695548"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baba</surname><given-names>TW</given-names></name><name name-style="western"><surname>Liska</surname><given-names>V</given-names></name><name name-style="western"><surname>Hofmann-Lehmann</surname><given-names>R</given-names></name><etal/></person-group><article-title>Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection</article-title>. <source>Nat Med</source>. <year>2000</year>;<volume>6</volume>:<fpage>200</fpage>&#8211;<lpage>206</lpage>.<pub-id pub-id-type="pmid">10655110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/72309</pub-id></mixed-citation></ref><ref id="bibr7-1179555717695548"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mascola</surname><given-names>JR.</given-names></name></person-group><article-title>Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1</article-title>. <source>Vaccine</source>. <year>2002</year>;<volume>20</volume>:<fpage>1922</fpage>&#8211;<lpage>1925</lpage>.<pub-id pub-id-type="pmid">11983246</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0264-410x(02)00068-3</pub-id></mixed-citation></ref><ref id="bibr8-1179555717695548"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mascola</surname><given-names>JR</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>MG</given-names></name><name name-style="western"><surname>Stiegler</surname><given-names>G</given-names></name><etal/></person-group><article-title>Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6 PD by passive transfer of neutralizing antibodies</article-title>. <source>J Virol</source>. <year>1999</year>;<volume>73</volume>:<fpage>4009</fpage>&#8211;<lpage>4018</lpage>.<pub-id pub-id-type="pmid">10196297</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jvi.73.5.4009-4018.1999</pub-id><pub-id pub-id-type="pmcid">PMC104180</pub-id></mixed-citation></ref><ref id="bibr9-1179555717695548"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buchbinder</surname><given-names>SP</given-names></name><name name-style="western"><surname>Mehrotra</surname><given-names>DV</given-names></name><name name-style="western"><surname>Duerr</surname><given-names>A</given-names></name><etal/></person-group><article-title>Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial</article-title>. <source>Lancet</source>. <year>2008</year>;<volume>372</volume>:<fpage>1881</fpage>&#8211;<lpage>1893</lpage>.<pub-id pub-id-type="pmid">19012954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(08)61591-3</pub-id><pub-id pub-id-type="pmcid">PMC2721012</pub-id></mixed-citation></ref><ref id="bibr10-1179555717695548"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gray</surname><given-names>GE</given-names></name><name name-style="western"><surname>Allen</surname><given-names>M</given-names></name><name name-style="western"><surname>Moodie</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study</article-title>. <source>Lancet Infect Dis</source>. <year>2011</year>;<volume>11</volume>:<fpage>507</fpage>&#8211;<lpage>515</lpage>.<pub-id pub-id-type="pmid">21570355</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(11)70098-6</pub-id><pub-id pub-id-type="pmcid">PMC3417349</pub-id></mixed-citation></ref><ref id="bibr11-1179555717695548"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rerks-Ngarm</surname><given-names>S</given-names></name><name name-style="western"><surname>Pitisuttithum</surname><given-names>P</given-names></name><name name-style="western"><surname>Nitayaphan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>361</volume>:<fpage>2209</fpage>&#8211;<lpage>2220</lpage>.<pub-id pub-id-type="pmid">19843557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa0908492</pub-id></mixed-citation></ref><ref id="bibr12-1179555717695548"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicholson</surname><given-names>O</given-names></name><name name-style="western"><surname>DiCandilo</surname><given-names>F</given-names></name><name name-style="western"><surname>Kublin</surname><given-names>J</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of the MRKAd5 gag HIV type 1 vaccine in a worldwide phase 1 study of healthy adults</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>2011</year>;<volume>27</volume>:<fpage>557</fpage>&#8211;<lpage>567</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/aid.2010.0151</pub-id><pub-id pub-id-type="pmcid">PMC3422055</pub-id><pub-id pub-id-type="pmid">20854108</pub-id></mixed-citation></ref><ref id="bibr13-1179555717695548"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hammer</surname><given-names>SM</given-names></name><name name-style="western"><surname>Sobieszczyk</surname><given-names>ME</given-names></name><name name-style="western"><surname>Janes</surname><given-names>H</given-names></name><etal/></person-group><article-title>Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine</article-title>. <source>N Engl J Med</source>. <year>2013</year>;<volume>369</volume>:<fpage>2083</fpage>&#8211;<lpage>2092</lpage>.<pub-id pub-id-type="pmid">24099601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1310566</pub-id><pub-id pub-id-type="pmcid">PMC4030634</pub-id></mixed-citation></ref><ref id="bibr14-1179555717695548"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Binley</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lybarger</surname><given-names>EA</given-names></name><name name-style="western"><surname>Crooks</surname><given-names>ET</given-names></name><etal/></person-group><article-title>Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C</article-title>. <source>J Virol</source>. <year>2008</year>;<volume>82</volume>:<fpage>11651</fpage>&#8211;<lpage>11668</lpage>.<pub-id pub-id-type="pmid">18815292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01762-08</pub-id><pub-id pub-id-type="pmcid">PMC2583680</pub-id></mixed-citation></ref><ref id="bibr15-1179555717695548"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Svehla</surname><given-names>K</given-names></name><name name-style="western"><surname>Louder</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals</article-title>. <source>J Virol</source>. <year>2009</year>;<volume>83</volume>:<fpage>1045</fpage>&#8211;<lpage>1059</lpage>.<pub-id pub-id-type="pmid">19004942</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01992-08</pub-id><pub-id pub-id-type="pmcid">PMC2612402</pub-id></mixed-citation></ref><ref id="bibr16-1179555717695548"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sather</surname><given-names>DN</given-names></name><name name-style="western"><surname>Armann</surname><given-names>J</given-names></name><name name-style="western"><surname>Ching</surname><given-names>LK</given-names></name><etal/></person-group><article-title>Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection</article-title>. <source>J Virol</source>. <year>2009</year>;<volume>83</volume>:<fpage>757</fpage>&#8211;<lpage>769</lpage>.<pub-id pub-id-type="pmid">18987148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02036-08</pub-id><pub-id pub-id-type="pmcid">PMC2612355</pub-id></mixed-citation></ref><ref id="bibr17-1179555717695548"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruck</surname><given-names>C</given-names></name><name name-style="western"><surname>Thiriart</surname><given-names>C</given-names></name><name name-style="western"><surname>Fabry</surname><given-names>L</given-names></name><etal/></person-group><article-title>HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees</article-title>. <source>Vaccine</source>. <year>1994</year>;<volume>12</volume>:<fpage>1141</fpage>&#8211;<lpage>1148</lpage>.<pub-id pub-id-type="pmid">7998425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0264-410x(94)90185-6</pub-id></mixed-citation></ref><ref id="bibr18-1179555717695548"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mascola</surname><given-names>JR</given-names></name><name name-style="western"><surname>Stiegler</surname><given-names>G</given-names></name><name name-style="western"><surname>VanCott</surname><given-names>TC</given-names></name><etal/></person-group><article-title>Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies</article-title>. <source>Nat Med</source>. <year>2000</year>;<volume>6</volume>:<fpage>207</fpage>&#8211;<lpage>210</lpage>.<pub-id pub-id-type="pmid">10655111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/72318</pub-id></mixed-citation></ref><ref id="bibr19-1179555717695548"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trkola</surname><given-names>A</given-names></name><name name-style="western"><surname>Kuster</surname><given-names>H</given-names></name><name name-style="western"><surname>Rusert</surname><given-names>P</given-names></name><etal/></person-group><article-title>Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies</article-title>. <source>Nat Med</source>. <year>2005</year>;<volume>11</volume>:<fpage>615</fpage>&#8211;<lpage>622</lpage>.<pub-id pub-id-type="pmid">15880120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm1244</pub-id></mixed-citation></ref><ref id="bibr20-1179555717695548"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hraber</surname><given-names>P</given-names></name><name name-style="western"><surname>Seaman</surname><given-names>MS</given-names></name><name name-style="western"><surname>Bailer</surname><given-names>RT</given-names></name><name name-style="western"><surname>Mascola</surname><given-names>JR</given-names></name><name name-style="western"><surname>Montefiori</surname><given-names>DC</given-names></name><name name-style="western"><surname>Korber</surname><given-names>BT.</given-names></name></person-group><article-title>Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection</article-title>. <source>AIDS</source>. <year>2014</year>;<volume>28</volume>:<fpage>163</fpage>&#8211;<lpage>169</lpage>.<pub-id pub-id-type="pmid">24361678</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/QAD.0000000000000106</pub-id><pub-id pub-id-type="pmcid">PMC4042313</pub-id></mixed-citation></ref><ref id="bibr21-1179555717695548"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hessell</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Poignard</surname><given-names>P</given-names></name><name name-style="western"><surname>Hunter</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques</article-title>. <source>Nat Med</source>. <year>2009</year>;<volume>15</volume>:<fpage>951</fpage>&#8211;<lpage>954</lpage>.<pub-id pub-id-type="pmid">19525965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.1974</pub-id><pub-id pub-id-type="pmcid">PMC4334439</pub-id></mixed-citation></ref><ref id="bibr22-1179555717695548"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bastian</surname><given-names>AR.</given-names></name></person-group><article-title>Microbicides that can Pop HIV-1</article-title>. <source>J Antivir Antiretrovir</source>. <year>2014</year>;<volume>6</volume>:<fpage>054</fpage>&#8211;<lpage>056</lpage>.</mixed-citation></ref><ref id="bibr23-1179555717695548"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bastian</surname><given-names>AR</given-names></name><name name-style="western"><surname>Contarino</surname><given-names>M</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>LD</given-names></name><etal/></person-group><article-title>Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions</article-title>. <source>Retrovirology</source>. <year>2013</year>;<volume>10</volume>:<fpage>153</fpage>.<pub-id pub-id-type="pmid">24330857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1742-4690-10-153</pub-id><pub-id pub-id-type="pmcid">PMC3878761</pub-id></mixed-citation></ref><ref id="bibr24-1179555717695548"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bastian</surname><given-names>AR</given-names></name><name name-style="western"><surname>McFadden</surname><given-names>K</given-names></name><name name-style="western"><surname>Duffy</surname><given-names>C</given-names></name><etal/></person-group><article-title>Cell-free HIV-1 virucidal action by modified peptide triazole inhibitors of Env gp120</article-title>. <source>ChemMedChem</source>. <year>2011</year>;<volume>6</volume>:<fpage>1335</fpage>&#8211;<lpage>1339</lpage>.<pub-id pub-id-type="pmid">21714095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cmdc.201100177</pub-id><pub-id pub-id-type="pmcid">PMC3517054</pub-id></mixed-citation></ref><ref id="bibr25-1179555717695548"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanders</surname><given-names>RW</given-names></name><name name-style="western"><surname>Vesanen</surname><given-names>M</given-names></name><name name-style="western"><surname>Schuelke</surname><given-names>N</given-names></name><etal/></person-group><article-title>Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1</article-title>. <source>J Virol</source>. <year>2002</year>;<volume>76</volume>:<fpage>8875</fpage>&#8211;<lpage>8889</lpage>.<pub-id pub-id-type="pmid">12163607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.76.17.8875-8889.2002</pub-id><pub-id pub-id-type="pmcid">PMC136973</pub-id></mixed-citation></ref><ref id="bibr26-1179555717695548"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khattar</surname><given-names>SK</given-names></name><name name-style="western"><surname>DeVico</surname><given-names>AL</given-names></name><name name-style="western"><surname>LaBranche</surname><given-names>CC</given-names></name><name name-style="western"><surname>Panda</surname><given-names>A</given-names></name><name name-style="western"><surname>Montefiori</surname><given-names>DC</given-names></name><name name-style="western"><surname>Samal</surname><given-names>SK.</given-names></name></person-group><article-title>Enhanced immune responses to HIV-1 envelope elicited by a vaccine regimen consisting of priming with Newcastle disease virus expressing HIV gp160 and boosting with gp120 and SOSIP gp140 proteins</article-title>. <source>J Virol</source>. <year>2016</year>;<volume>90</volume>:<fpage>1682</fpage>&#8211;<lpage>1686</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02847-15</pub-id><pub-id pub-id-type="pmcid">PMC4719621</pub-id><pub-id pub-id-type="pmid">26581986</pub-id></mixed-citation></ref><ref id="bibr27-1179555717695548"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wardemann</surname><given-names>H</given-names></name><name name-style="western"><surname>Yurasov</surname><given-names>S</given-names></name><name name-style="western"><surname>Schaefer</surname><given-names>A</given-names></name><name name-style="western"><surname>Young</surname><given-names>JW</given-names></name><name name-style="western"><surname>Meffre</surname><given-names>E</given-names></name><name name-style="western"><surname>Nussenzweig</surname><given-names>MC.</given-names></name></person-group><article-title>Predominant autoantibody production by early human B cell precursors</article-title>. <source>Science</source>. <year>2003</year>;<volume>301</volume>:<fpage>1374</fpage>&#8211;<lpage>1377</lpage>.<pub-id pub-id-type="pmid">12920303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1086907</pub-id></mixed-citation></ref><ref id="bibr28-1179555717695548"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wardemann</surname><given-names>H</given-names></name><name name-style="western"><surname>Nussenzweig</surname><given-names>MC.</given-names></name></person-group><article-title>B-cell self-tolerance in humans</article-title>. <source>Adv Immunol</source>. <year>2007</year>;<volume>95</volume>:<fpage>83</fpage>&#8211;<lpage>110</lpage>.<pub-id pub-id-type="pmid">17869611</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0065-2776(07)95003-8</pub-id></mixed-citation></ref><ref id="bibr29-1179555717695548"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verkoczy</surname><given-names>L</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>M</given-names></name><name name-style="western"><surname>Holl</surname><given-names>TM</given-names></name><etal/></person-group><article-title>Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2010</year>;<volume>107</volume>:<fpage>181</fpage>&#8211;<lpage>186</lpage>.<pub-id pub-id-type="pmid">20018688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0912914107</pub-id><pub-id pub-id-type="pmcid">PMC2806760</pub-id></mixed-citation></ref><ref id="bibr30-1179555717695548"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verkoczy</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bouton-Verville</surname><given-names>H</given-names></name><etal/></person-group><article-title>Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH &#215; VL knockin mice reveals multiple tolerance controls</article-title>. <source>J Immunol</source>. <year>2011</year>;<volume>187</volume>:<fpage>3785</fpage>&#8211;<lpage>3797</lpage>.<pub-id pub-id-type="pmid">21908739</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1101633</pub-id><pub-id pub-id-type="pmcid">PMC3192533</pub-id></mixed-citation></ref><ref id="bibr31-1179555717695548"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>G</given-names></name><name name-style="western"><surname>Holl</surname><given-names>TM</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies</article-title>. <source>J Exp Med</source>. <year>2013</year>;<volume>210</volume>:<fpage>241</fpage>&#8211;<lpage>256</lpage>.<pub-id pub-id-type="pmid">23359068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20121977</pub-id><pub-id pub-id-type="pmcid">PMC3570098</pub-id></mixed-citation></ref><ref id="bibr32-1179555717695548"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>G</given-names></name><name name-style="western"><surname>Holl</surname><given-names>T</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Kynureninase is the conserved self-antigen mimicked by the 2F5 neutralizing epitope of HIV-1 gp41</article-title>. <source>J Immunol</source>. <year>2012</year>;<volume>188</volume>:<fpage>105</fpage>&#8211;<lpage>135</lpage>.</mixed-citation></ref><ref id="bibr33-1179555717695548"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gray</surname><given-names>ES</given-names></name><name name-style="western"><surname>Madiga</surname><given-names>MC</given-names></name><name name-style="western"><surname>Hermanus</surname><given-names>T</given-names></name><etal/></person-group><article-title>The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection</article-title>. <source>J Virol</source>. <year>2011</year>;<volume>85</volume>:<fpage>4828</fpage>&#8211;<lpage>4840</lpage>.<pub-id pub-id-type="pmid">21389135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00198-11</pub-id><pub-id pub-id-type="pmcid">PMC3126191</pub-id></mixed-citation></ref><ref id="bibr34-1179555717695548"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haynes</surname><given-names>BF</given-names></name><name name-style="western"><surname>Kelsoe</surname><given-names>G</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>SC</given-names></name><name name-style="western"><surname>Kepler</surname><given-names>TB.</given-names></name></person-group><article-title>B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study</article-title>. <source>Nat Biotechnol</source>. <year>2012</year>;<volume>30</volume>:<fpage>423</fpage>&#8211;<lpage>433</lpage>.<pub-id pub-id-type="pmid">22565972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.2197</pub-id><pub-id pub-id-type="pmcid">PMC3512202</pub-id></mixed-citation></ref><ref id="bibr35-1179555717695548"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jardine</surname><given-names>J</given-names></name><name name-style="western"><surname>Julien</surname><given-names>J-P</given-names></name><name name-style="western"><surname>Menis</surname><given-names>S</given-names></name><etal/></person-group><article-title>Rational HIV immunogen design to target specific germline B cell receptors</article-title>. <source>Science</source>. <year>2013</year>;<volume>340</volume>:<fpage>711</fpage>&#8211;<lpage>716</lpage>.<pub-id pub-id-type="pmid">23539181</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1234150</pub-id><pub-id pub-id-type="pmcid">PMC3689846</pub-id></mixed-citation></ref><ref id="bibr36-1179555717695548"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>F</given-names></name><name name-style="western"><surname>Bonsignori</surname><given-names>M</given-names></name><name name-style="western"><surname>Liao</surname><given-names>H-X</given-names></name><etal/></person-group><article-title>Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies</article-title>. <source>Cell</source>. <year>2014</year>;<volume>158</volume>:<fpage>481</fpage>&#8211;<lpage>491</lpage>.<pub-id pub-id-type="pmid">25065977</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2014.06.022</pub-id><pub-id pub-id-type="pmcid">PMC4150607</pub-id></mixed-citation></ref><ref id="bibr37-1179555717695548"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Schramm</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Maturation and diversity of the VRC01-antibody lineage over 15 years of chronic HIV-1 infection</article-title>. <source>Cell</source>. <year>2015</year>;<volume>161</volume>:<fpage>470</fpage>&#8211;<lpage>485</lpage>.<pub-id pub-id-type="pmid">25865483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2015.03.004</pub-id><pub-id pub-id-type="pmcid">PMC4706178</pub-id></mixed-citation></ref><ref id="bibr38-1179555717695548"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGuire</surname><given-names>AT</given-names></name><name name-style="western"><surname>Dreyer</surname><given-names>AM</given-names></name><name name-style="western"><surname>Carbonetti</surname><given-names>S</given-names></name><etal/></person-group><article-title>Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies</article-title>. <source>Science</source>. <year>2014</year>;<volume>346</volume>:<fpage>1380</fpage>&#8211;<lpage>1383</lpage>.<pub-id pub-id-type="pmid">25504724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1259206</pub-id><pub-id pub-id-type="pmcid">PMC4290850</pub-id></mixed-citation></ref><ref id="bibr39-1179555717695548"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>AW</given-names></name><name name-style="western"><surname>Navis</surname><given-names>M</given-names></name><name name-style="western"><surname>Isitman</surname><given-names>G</given-names></name><etal/></person-group><article-title>Activation of NK cells by ADCC responses during early HIV infection</article-title>. <source>Viral Immunol</source>. <year>2011</year>;<volume>24</volume>:<fpage>171</fpage>&#8211;<lpage>175</lpage>.<pub-id pub-id-type="pmid">21449728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/vim.2010.0108</pub-id><pub-id pub-id-type="pmcid">PMC3070001</pub-id></mixed-citation></ref><ref id="bibr40-1179555717695548"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johansson</surname><given-names>SE</given-names></name><name name-style="western"><surname>Rollman</surname><given-names>E</given-names></name><name name-style="western"><surname>Chung</surname><given-names>AW</given-names></name><etal/></person-group><article-title>NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients</article-title>. <source>Viral Immunol</source>. <year>2011</year>;<volume>24</volume>:<fpage>359</fpage>&#8211;<lpage>368</lpage>.<pub-id pub-id-type="pmid">21958370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/vim.2011.0025</pub-id></mixed-citation></ref><ref id="bibr41-1179555717695548"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>AW</given-names></name><name name-style="western"><surname>Schoen</surname><given-names>MK</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>H</given-names></name><etal/></person-group><article-title>Polyfunctional non-neutralizing Fc-antibody responses in acute HIV infection predict spontaneous viral control</article-title>. <source>AIDS Res Hum Retrovir</source>. <year>2014</year>;<volume>30</volume>:<fpage>A89</fpage>.</mixed-citation></ref><ref id="bibr42-1179555717695548"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ackerman</surname><given-names>ME</given-names></name><name name-style="western"><surname>Mikhailova</surname><given-names>A</given-names></name><name name-style="western"><surname>Brown</surname><given-names>EP</given-names></name><etal/></person-group><article-title>Polyfunctional HIV-specific antibody responses are associated with spontaneous HIV control</article-title>. <source>PLoS Pathog</source>. <year>2016</year>;<volume>12</volume>:<fpage>e1005315</fpage>.<pub-id pub-id-type="pmid">26745376</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1005315</pub-id><pub-id pub-id-type="pmcid">PMC4706315</pub-id></mixed-citation></ref><ref id="bibr43-1179555717695548"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gunn</surname><given-names>B</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>J</given-names></name><name name-style="western"><surname>Shansab</surname><given-names>M</given-names></name><etal/></person-group><article-title>Enhanced binding of antibodies generated during chronic HIV infection to mucus component MUC16</article-title>. <source>Mucosal Immunol</source>. <year>2016</year>;<volume>9</volume>:<fpage>1549</fpage>&#8211;<lpage>1558</lpage>.<pub-id pub-id-type="pmid">26960182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mi.2016.8</pub-id><pub-id pub-id-type="pmcid">PMC5017893</pub-id></mixed-citation></ref><ref id="bibr44-1179555717695548"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loret</surname><given-names>EP</given-names></name><name name-style="western"><surname>Darque</surname><given-names>A</given-names></name><name name-style="western"><surname>Jouve</surname><given-names>E</given-names></name><etal/></person-group><article-title>Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial</article-title>. <source>Retrovirology</source>. <year>2016</year>;<volume>13</volume>:<fpage>21</fpage>.<pub-id pub-id-type="pmid">27036656</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12977-016-0251-3</pub-id><pub-id pub-id-type="pmcid">PMC4818470</pub-id></mixed-citation></ref><ref id="bibr45-1179555717695548"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toromanoff</surname><given-names>A</given-names></name><name name-style="western"><surname>Ch&#233;rel</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guilbaud</surname><given-names>M</given-names></name><etal/></person-group><article-title>Safety and efficacy of regional intravenous (RI) versus intramuscular (IM) delivery of rAAV1 and rAAV8 to nonhuman primate skeletal muscle</article-title>. <source>Mol Ther</source>. <year>2008</year>;<volume>16</volume>:<fpage>1291</fpage>&#8211;<lpage>1299</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mt.2008.87</pub-id><pub-id pub-id-type="pmid">28178483</pub-id></mixed-citation></ref><ref id="bibr46-1179555717695548"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schnepp</surname><given-names>BC</given-names></name><name name-style="western"><surname>Clark</surname><given-names>KR</given-names></name><name name-style="western"><surname>Klemanski</surname><given-names>DL</given-names></name><name name-style="western"><surname>Pacak</surname><given-names>CA</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>PR.</given-names></name></person-group><article-title>Genetic fate of recombinant adeno-associated virus vector genomes in muscle</article-title>. <source>J Virol</source>. <year>2003</year>;<volume>77</volume>:<fpage>3495</fpage>&#8211;<lpage>3504</lpage>.<pub-id pub-id-type="pmid">12610125</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.77.6.3495-3504.2003</pub-id><pub-id pub-id-type="pmcid">PMC149530</pub-id></mixed-citation></ref><ref id="bibr47-1179555717695548"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schnepp</surname><given-names>BC</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>RL</given-names></name><name name-style="western"><surname>Clark</surname><given-names>KR</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>PR.</given-names></name></person-group><article-title>Infectious molecular clones of adeno-associated virus isolated directly from human tissues</article-title>. <source>J Virol</source>. <year>2009</year>;<volume>83</volume>:<fpage>1456</fpage>&#8211;<lpage>1464</lpage>.<pub-id pub-id-type="pmid">19019948</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01686-08</pub-id><pub-id pub-id-type="pmcid">PMC2620885</pub-id></mixed-citation></ref><ref id="bibr48-1179555717695548"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calcedo</surname><given-names>R</given-names></name><name name-style="western"><surname>Franco</surname><given-names>J</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Preexisting neutralizing antibodies to adeno-associated virus capsids in large animals other than monkeys may confound in vivo gene therapy studies</article-title>. <source>Hum Gene Ther Methods</source>. <year>2015</year>;<volume>26</volume>:<fpage>103</fpage>&#8211;<lpage>105</lpage>.<pub-id pub-id-type="pmid">26067568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/hgtb.2015.082</pub-id><pub-id pub-id-type="pmcid">PMC4492586</pub-id></mixed-citation></ref><ref id="bibr49-1179555717695548"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calcedo</surname><given-names>R</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>JM.</given-names></name></person-group><article-title>AAV natural infection induces broad cross-neutralizing antibody responses to multiple AAV serotypes in chimpanzees [published online ahead of print June 1, 2016]</article-title>. <source>Hum Gene Ther Clin Dev</source>. doi:<pub-id pub-id-type="doi">10.1089/hum.2016.048.</pub-id><pub-id pub-id-type="pmcid">PMC4932656</pub-id><pub-id pub-id-type="pmid">27314914</pub-id></mixed-citation></ref><ref id="bibr50-1179555717695548"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>PR</given-names></name><name name-style="western"><surname>Schnepp</surname><given-names>BC</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys</article-title>. <source>Nat Med</source>. <year>2009</year>;<volume>15</volume>:<fpage>901</fpage>&#8211;<lpage>906</lpage>.<pub-id pub-id-type="pmid">19448633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.1967</pub-id><pub-id pub-id-type="pmcid">PMC2723177</pub-id></mixed-citation></ref><ref id="bibr51-1179555717695548"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobson</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lowy</surname><given-names>I</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>CV</given-names></name><etal/></person-group><article-title>Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults</article-title>. <source>J Infect Dis</source>. <year>2000</year>;<volume>182</volume>:<fpage>326</fpage>&#8211;<lpage>329</lpage>.<pub-id pub-id-type="pmid">10882617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/315698</pub-id></mixed-citation></ref><ref id="bibr52-1179555717695548"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fletcher</surname><given-names>CV</given-names></name><name name-style="western"><surname>DeVille</surname><given-names>JG</given-names></name><name name-style="western"><surname>Samson</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected children</article-title>. <source>J Allergy Clin Immunol</source>. <year>2007</year>;<volume>119</volume>:<fpage>747</fpage>&#8211;<lpage>750</lpage>.<pub-id pub-id-type="pmid">17336619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaci.2006.10.045</pub-id><pub-id pub-id-type="pmcid">PMC1910693</pub-id></mixed-citation></ref><ref id="bibr53-1179555717695548"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gardner</surname><given-names>MR</given-names></name><name name-style="western"><surname>Kattenhorn</surname><given-names>LM</given-names></name><name name-style="western"><surname>Kondur</surname><given-names>HR</given-names></name><etal/></person-group><article-title>AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges</article-title>. <source>Nature</source>. <year>2015</year>;<volume>519</volume>:<fpage>87</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="pmid">25707797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature14264</pub-id><pub-id pub-id-type="pmcid">PMC4352131</pub-id></mixed-citation></ref><ref id="bibr54-1179555717695548"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deere</surname><given-names>JD</given-names></name><name name-style="western"><surname>Chang</surname><given-names>WW</given-names></name><name name-style="western"><surname>Castillo</surname><given-names>LD</given-names></name><etal/></person-group><article-title>Utilizing a TLR5-adjuvanted cytomegalovirus as a lentiviral vaccine in the nonhuman primate model for AIDS</article-title>. <source>PLoS ONE</source>. <year>2016</year>;<volume>11</volume>:<fpage>e0155629</fpage>.<pub-id pub-id-type="pmid">27182601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0155629</pub-id><pub-id pub-id-type="pmcid">PMC4868283</pub-id></mixed-citation></ref><ref id="bibr55-1179555717695548"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baden</surname><given-names>LR</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>SR</given-names></name><name name-style="western"><surname>Seaman</surname><given-names>MS</given-names></name><etal/></person-group><article-title>First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)</article-title>. <source>J Infect Dis</source>. <year>2012</year>;<volume>207</volume>:<fpage>240</fpage>&#8211;<lpage>247</lpage>.<pub-id pub-id-type="pmid">23125444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jis670</pub-id><pub-id pub-id-type="pmcid">PMC3532831</pub-id></mixed-citation></ref><ref id="bibr56-1179555717695548"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chahroudi</surname><given-names>A</given-names></name><name name-style="western"><surname>Silvestri</surname><given-names>G.</given-names></name></person-group><article-title>HIV and Tfh cells: circulating new ideas to identify and protect</article-title>. <source>Immunity</source>. <year>2016</year>;<volume>44</volume>:<fpage>16</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="pmid">26789919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2015.12.016</pub-id></mixed-citation></ref><ref id="bibr57-1179555717695548"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindqvist</surname><given-names>M</given-names></name><name name-style="western"><surname>van Lunzen</surname><given-names>J</given-names></name><name name-style="western"><surname>Soghoian</surname><given-names>DZ</given-names></name><etal/></person-group><article-title>Expansion of HIV-specific T follicular helper cells in chronic HIV infection</article-title>. <source>J Clin Invest</source>. <year>2012</year>;<volume>122</volume>:<fpage>3271</fpage>&#8211;<lpage>3280</lpage>.<pub-id pub-id-type="pmid">22922259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI64314</pub-id><pub-id pub-id-type="pmcid">PMC3428098</pub-id></mixed-citation></ref><ref id="bibr58-1179555717695548"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moir</surname><given-names>S</given-names></name><name name-style="western"><surname>Fauci</surname><given-names>AS.</given-names></name></person-group><article-title>B cells in HIV infection and disease</article-title>. <source>Nat Rev Immunol</source>. <year>2009</year>;<volume>9</volume>:<fpage>235</fpage>&#8211;<lpage>245</lpage>.<pub-id pub-id-type="pmid">19319142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri2524</pub-id><pub-id pub-id-type="pmcid">PMC2779527</pub-id></mixed-citation></ref><ref id="bibr59-1179555717695548"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perreau</surname><given-names>M</given-names></name><name name-style="western"><surname>Savoye</surname><given-names>A-L</given-names></name><name name-style="western"><surname>De Crignis</surname><given-names>E</given-names></name><etal/></person-group><article-title>Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production</article-title>. <source>J Exp Med</source>. <year>2013</year>;<volume>210</volume>:<fpage>143</fpage>&#8211;<lpage>156</lpage>.<pub-id pub-id-type="pmid">23254284</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20121932</pub-id><pub-id pub-id-type="pmcid">PMC3549706</pub-id></mixed-citation></ref><ref id="bibr60-1179555717695548"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miles</surname><given-names>B</given-names></name><name name-style="western"><surname>Connick</surname><given-names>E.</given-names></name></person-group><article-title>T FH in HIV latency and as sources of replication-competent virus</article-title>. <source>Trends Microbiol</source>. <year>2016</year>;<volume>24</volume>:<fpage>338</fpage>&#8211;<lpage>344</lpage>.<pub-id pub-id-type="pmid">26947191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tim.2016.02.006</pub-id><pub-id pub-id-type="pmcid">PMC4841704</pub-id></mixed-citation></ref><ref id="bibr61-1179555717695548"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kohler</surname><given-names>SL</given-names></name><name name-style="western"><surname>Pham</surname><given-names>MN</given-names></name><name name-style="western"><surname>Folkvord</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Germinal center T follicular helper cells are highly permissive to HIV-1 and alter their phenotype during virus replication</article-title>. <source>J Immunol</source>. <year>2016</year>;<volume>196</volume>:<fpage>2711</fpage>&#8211;<lpage>2722</lpage>.<pub-id pub-id-type="pmid">26873986</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1502174</pub-id><pub-id pub-id-type="pmcid">PMC4779697</pub-id></mixed-citation></ref><ref id="bibr62-1179555717695548"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cubas</surname><given-names>RA</given-names></name><name name-style="western"><surname>Mudd</surname><given-names>JC</given-names></name><name name-style="western"><surname>Savoye</surname><given-names>A-L</given-names></name><etal/></person-group><article-title>Inadequate T follicular cell help impairs B cell immunity during HIV infection</article-title>. <source>Nat Med</source>. <year>2013</year>;<volume>19</volume>:<fpage>494</fpage>&#8211;<lpage>499</lpage>.<pub-id pub-id-type="pmid">23475201</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.3109</pub-id><pub-id pub-id-type="pmcid">PMC3843317</pub-id></mixed-citation></ref><ref id="bibr63-1179555717695548"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colineau</surname><given-names>L</given-names></name><name name-style="western"><surname>Rouers</surname><given-names>A</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>T</given-names></name><etal/></person-group><article-title>HIV-infected spleens present altered follicular helper T cell (Tfh) subsets and skewed B cell maturation</article-title>. <source>PLoS ONE</source>. <year>2015</year>;<volume>10</volume>:<fpage>e0140978</fpage>.<pub-id pub-id-type="pmid">26501424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0140978</pub-id><pub-id pub-id-type="pmcid">PMC4621058</pub-id></mixed-citation></ref><ref id="bibr64-1179555717695548"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pereyra</surname><given-names>F</given-names></name><name name-style="western"><surname>Heckerman</surname><given-names>D</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>JM</given-names></name><etal/></person-group><article-title>HIV control is mediated in part by CD8+ T-cell targeting of specific epitopes</article-title>. <source>J Virol</source>. <year>2014</year>;<volume>88</volume>:<fpage>12937</fpage>&#8211;<lpage>12948</lpage>.<pub-id pub-id-type="pmid">25165115</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01004-14</pub-id><pub-id pub-id-type="pmcid">PMC4249072</pub-id></mixed-citation></ref><ref id="bibr65-1179555717695548"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>F</given-names></name><name name-style="western"><surname>Neelapu</surname><given-names>SS.</given-names></name></person-group><article-title>CXCR5+CD8+ T cells are localized in B cell follicles and germinal centers and exhibit regulatory and anti-tumor function</article-title>. <source>J Immunother Cancer</source>. <year>2015</year>;<volume>3</volume>:<fpage>P321</fpage>.</mixed-citation></ref><ref id="bibr66-1179555717695548"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miles</surname><given-names>B</given-names></name><name name-style="western"><surname>Miller</surname><given-names>S</given-names></name><name name-style="western"><surname>Folkvord</surname><given-names>J</given-names></name><name name-style="western"><surname>Levy</surname><given-names>D</given-names></name><name name-style="western"><surname>Rakasz</surname><given-names>E</given-names></name><name name-style="western"><surname>Skinner</surname><given-names>P.</given-names></name></person-group><article-title>Follicular regulatory CD8 T cells impair the germinal center response in SIV and ex vivo HIV infection</article-title>. <source>PLoS Pathog</source>. <year>2016</year>;<volume>12</volume>:<fpage>e1005924</fpage>.<pub-id pub-id-type="pmid">27716848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1005924</pub-id><pub-id pub-id-type="pmcid">PMC5055335</pub-id></mixed-citation></ref><ref id="bibr67-1179555717695548"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nurieva</surname><given-names>RI</given-names></name><name name-style="western"><surname>Chung</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>D</given-names></name><etal/></person-group><article-title>Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages</article-title>. <source>Immunity</source>. <year>2008</year>;<volume>29</volume>:<fpage>138</fpage>&#8211;<lpage>149</lpage>.<pub-id pub-id-type="pmid">18599325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2008.05.009</pub-id><pub-id pub-id-type="pmcid">PMC2556461</pub-id></mixed-citation></ref><ref id="bibr68-1179555717695548"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eto</surname><given-names>D</given-names></name><name name-style="western"><surname>Lao</surname><given-names>C</given-names></name><name name-style="western"><surname>DiToro</surname><given-names>D</given-names></name><etal/></person-group><article-title>IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation</article-title>. <source>PLoS ONE</source>. <year>2011</year>;<volume>6</volume>:<fpage>e17739</fpage>.<pub-id pub-id-type="pmid">21423809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0017739</pub-id><pub-id pub-id-type="pmcid">PMC3056724</pub-id></mixed-citation></ref><ref id="bibr69-1179555717695548"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>CS</given-names></name><name name-style="western"><surname>Suryani</surname><given-names>S</given-names></name><name name-style="western"><surname>Avery</surname><given-names>DT</given-names></name><etal/></person-group><article-title>Early commitment of na&#239;ve human CD4(+) T cells to the T follicular helper (T(FH)) cell lineage is induced by IL-12</article-title>. <source>Immunol Cell Biol</source>. <year>2009</year>;<volume>87</volume>:<fpage>590</fpage>&#8211;<lpage>600</lpage>.<pub-id pub-id-type="pmid">19721453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/icb.2009.64</pub-id></mixed-citation></ref><ref id="bibr70-1179555717695548"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hardtke</surname><given-names>S</given-names></name><name name-style="western"><surname>Ohl</surname><given-names>L</given-names></name><name name-style="western"><surname>F&#246;rster</surname><given-names>R.</given-names></name></person-group><article-title>Balanced expression of CXCR5 and CCR7 on follicular T helper cells determines their transient positioning to lymph node follicles and is essential for efficient B-cell help</article-title>. <source>Blood</source>. <year>2005</year>;<volume>106</volume>:<fpage>1924</fpage>&#8211;<lpage>1931</lpage>.<pub-id pub-id-type="pmid">15899919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2004-11-4494</pub-id></mixed-citation></ref><ref id="bibr71-1179555717695548"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Guinoa</surname><given-names>JS</given-names></name><name name-style="western"><surname>Barrio</surname><given-names>L</given-names></name><name name-style="western"><surname>Mellado</surname><given-names>M</given-names></name><name name-style="western"><surname>Carrasco</surname><given-names>YR.</given-names></name></person-group><article-title>CXCL13/CXCR5 signaling enhances BCR-triggered B-cell activation by shaping cell dynamics</article-title>. <source>Blood</source>. <year>2011</year>;<volume>118</volume>:<fpage>1560</fpage>&#8211;<lpage>1569</lpage>.<pub-id pub-id-type="pmid">21659539</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2011-01-332106</pub-id></mixed-citation></ref><ref id="bibr72-1179555717695548"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pedros</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hu</surname><given-names>JK</given-names></name><etal/></person-group><article-title>A TRAF-like motif of the inducible costimulator ICOS controls development of germinal center TFH cells via the kinase TBK1</article-title>. <source>Nat Immunol</source>. <year>2016</year>;<volume>17</volume>:<fpage>825</fpage>&#8211;<lpage>833</lpage>.<pub-id pub-id-type="pmid">27135603</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ni.3463</pub-id><pub-id pub-id-type="pmcid">PMC4915981</pub-id></mixed-citation></ref><ref id="bibr73-1179555717695548"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sage</surname><given-names>PT</given-names></name><name name-style="western"><surname>Francisco</surname><given-names>LM</given-names></name><name name-style="western"><surname>Carman</surname><given-names>CV</given-names></name><name name-style="western"><surname>Sharpe</surname><given-names>AH.</given-names></name></person-group><article-title>PD-1 controls lymph node and blood T follicular regulatory cells</article-title>. <source>Nat Immunol</source>. <year>2013</year>;<volume>14</volume>:<fpage>152</fpage>&#8211;<lpage>161</lpage>.<pub-id pub-id-type="pmid">23242415</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ni.2496</pub-id><pub-id pub-id-type="pmcid">PMC3788614</pub-id></mixed-citation></ref><ref id="bibr74-1179555717695548"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Good-Jacobson</surname><given-names>KL</given-names></name><name name-style="western"><surname>Song</surname><given-names>E</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>S</given-names></name><name name-style="western"><surname>Sharpe</surname><given-names>AH</given-names></name><name name-style="western"><surname>Shlomchik</surname><given-names>MJ.</given-names></name></person-group><article-title>CD80 expression on B cells regulates murine T follicular helper development, germinal center B cell survival, and plasma cell generation</article-title>. <source>J Immunol</source>. <year>2012</year>;<volume>188</volume>:<fpage>4217</fpage>&#8211;<lpage>4225</lpage>.<pub-id pub-id-type="pmid">22450810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1102885</pub-id><pub-id pub-id-type="pmcid">PMC3331930</pub-id></mixed-citation></ref><ref id="bibr75-1179555717695548"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adem</surname><given-names>J</given-names></name><name name-style="western"><surname>H&#228;m&#228;l&#228;inen</surname><given-names>A</given-names></name><name name-style="western"><surname>Ropponen</surname><given-names>A</given-names></name><etal/></person-group><article-title>ERK1/2 has an essential role in B cell receptor- and CD40-induced signaling in an in vitro model of germinal center B cell selection</article-title>. <source>Mol Immunol</source>. <year>2015</year>;<volume>67</volume>:<fpage>240</fpage>&#8211;<lpage>247</lpage>.<pub-id pub-id-type="pmid">26054744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molimm.2015.05.017</pub-id></mixed-citation></ref><ref id="bibr76-1179555717695548"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linterman</surname><given-names>MA</given-names></name><name name-style="western"><surname>Beaton</surname><given-names>L</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D</given-names></name><etal/></person-group><article-title>IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses</article-title>. <source>J Exp Med</source>. <year>2010</year>;<volume>207</volume>:<fpage>353</fpage>&#8211;<lpage>363</lpage>.<pub-id pub-id-type="pmid">20142429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20091738</pub-id><pub-id pub-id-type="pmcid">PMC2822609</pub-id></mixed-citation></ref><ref id="bibr77-1179555717695548"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zotos</surname><given-names>D</given-names></name><name name-style="western"><surname>Coquet</surname><given-names>JM</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism</article-title>. <source>J Exp Med</source>. <year>2010</year>;<volume>207</volume>:<fpage>365</fpage>&#8211;<lpage>378</lpage>.<pub-id pub-id-type="pmid">20142430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20091777</pub-id><pub-id pub-id-type="pmcid">PMC2822601</pub-id></mixed-citation></ref><ref id="bibr78-1179555717695548"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozaki</surname><given-names>K</given-names></name><name name-style="western"><surname>Spolski</surname><given-names>R</given-names></name><name name-style="western"><surname>Feng</surname><given-names>CG</given-names></name><etal/></person-group><article-title>A critical role for IL-21 in regulating immunoglobulin production</article-title>. <source>Science</source>. <year>2002</year>;<volume>298</volume>:<fpage>1630</fpage>&#8211;<lpage>1634</lpage>.<pub-id pub-id-type="pmid">12446913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1077002</pub-id></mixed-citation></ref><ref id="bibr79-1179555717695548"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Good-Jacobson</surname><given-names>KL</given-names></name><name name-style="western"><surname>Szumilas</surname><given-names>CG</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Sharpe</surname><given-names>AH</given-names></name><name name-style="western"><surname>Tomayko</surname><given-names>MM</given-names></name><name name-style="western"><surname>Shlomchik</surname><given-names>MJ.</given-names></name></person-group><article-title>PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells</article-title>. <source>Nat Immunol</source>. <year>2010</year>;<volume>11</volume>:<fpage>535</fpage>&#8211;<lpage>542</lpage>.<pub-id pub-id-type="pmid">20453843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ni.1877</pub-id><pub-id pub-id-type="pmcid">PMC2874069</pub-id></mixed-citation></ref><ref id="bibr80-1179555717695548"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>K</given-names></name><name name-style="western"><surname>Altfeld</surname><given-names>M</given-names></name><name name-style="western"><surname>Alter</surname><given-names>G</given-names></name><name name-style="western"><surname>Stamatatos</surname><given-names>L.</given-names></name></person-group><article-title>Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection</article-title>. <source>J Virol</source>. <year>2014</year>;<volume>88</volume>:<fpage>13310</fpage>&#8211;<lpage>13321</lpage>.<pub-id pub-id-type="pmid">25210168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02186-14</pub-id><pub-id pub-id-type="pmcid">PMC4249103</pub-id></mixed-citation></ref><ref id="bibr81-1179555717695548"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Locci</surname><given-names>M</given-names></name><name name-style="western"><surname>Havenar-Daughton</surname><given-names>C</given-names></name><name name-style="western"><surname>Landais</surname><given-names>E</given-names></name><etal/></person-group><article-title>Human Circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses</article-title>. <source>Immunity</source>. <year>2013</year>;<volume>39</volume>:<fpage>758</fpage>&#8211;<lpage>769</lpage>.<pub-id pub-id-type="pmid">24035365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2013.08.031</pub-id><pub-id pub-id-type="pmcid">PMC3996844</pub-id></mixed-citation></ref><ref id="bibr82-1179555717695548"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pallikkuth</surname><given-names>S</given-names></name><name name-style="western"><surname>Parmigiani</surname><given-names>A</given-names></name><name name-style="western"><surname>Silva</surname><given-names>SY</given-names></name><etal/></person-group><article-title>Impaired peripheral blood T-follicular helper cell function in HIV-infected nonresponders to the 2009 H1N1/09 vaccine</article-title>. <source>Blood</source>. <year>2012</year>;<volume>120</volume>:<fpage>985</fpage>&#8211;<lpage>993</lpage>.<pub-id pub-id-type="pmid">22692510</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2011-12-396648</pub-id><pub-id pub-id-type="pmcid">PMC3412336</pub-id></mixed-citation></ref><ref id="bibr83-1179555717695548"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>J</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>LM</given-names></name><name name-style="western"><surname>Leong</surname><given-names>YA</given-names></name><etal/></person-group><article-title>Circulating precursor CCR7(lo)PD-1(hi) CXCR5<sup>+</sup> CD4<sup>+</sup> T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure</article-title>. <source>Immunity</source>. <year>2013</year>;<volume>39</volume>:<fpage>770</fpage>&#8211;<lpage>781</lpage>.<pub-id pub-id-type="pmid">24138884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2013.09.007</pub-id></mixed-citation></ref><ref id="bibr84-1179555717695548"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boswell</surname><given-names>KL</given-names></name><name name-style="western"><surname>Paris</surname><given-names>R</given-names></name><name name-style="western"><surname>Boritz</surname><given-names>E</given-names></name><etal/></person-group><article-title>Loss of circulating CD4 T cells with B cell helper function during chronic HIV infection</article-title>. <source>PLoS Pathog</source>. <year>2014</year>;<volume>10</volume>:<fpage>e1003853</fpage>.<pub-id pub-id-type="pmid">24497824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1003853</pub-id><pub-id pub-id-type="pmcid">PMC3911819</pub-id></mixed-citation></ref><ref id="bibr85-1179555717695548"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Havenar-Daughton</surname><given-names>C</given-names></name><name name-style="western"><surname>Lindqvist</surname><given-names>M</given-names></name><name name-style="western"><surname>Heit</surname><given-names>A</given-names></name><etal/></person-group><article-title>CXCL13 is a plasma biomarker of germinal center activity</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2016</year>;<volume>113</volume>:<fpage>2702</fpage>&#8211;<lpage>2707</lpage>.<pub-id pub-id-type="pmid">26908875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1520112113</pub-id><pub-id pub-id-type="pmcid">PMC4790995</pub-id></mixed-citation></ref><ref id="bibr86-1179555717695548"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Landais</surname><given-names>E</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Havenar-Daughton</surname><given-names>C</given-names></name><etal/></person-group><article-title>Broadly neutralizing antibody responses in a large longitudinal sub-Saharan HIV primary infection cohort</article-title>. <source>PLoS Pathog</source>. <year>2016</year>;<volume>12</volume>:<fpage>e1005369</fpage>.<pub-id pub-id-type="pmid">26766578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1005369</pub-id><pub-id pub-id-type="pmcid">PMC4713061</pub-id></mixed-citation></ref><ref id="bibr87-1179555717695548"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Havenar-Daughton</surname><given-names>C</given-names></name><name name-style="western"><surname>Carnathan</surname><given-names>DG</given-names></name><name name-style="western"><surname>De</surname><given-names>la</given-names></name><name name-style="western"><surname>Pe&#241;a</surname><given-names>AT</given-names></name><etal/></person-group><article-title>Direct probing of germinal center responses reveals immunological features and bottlenecks for neutralizing antibody responses to HIV Env trimer</article-title>. <source>Cell Rep</source>. <year>2016</year>;<volume>17</volume>:<fpage>2195</fpage>&#8211;<lpage>2209</lpage>.<pub-id pub-id-type="pmid">27880897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2016.10.085</pub-id><pub-id pub-id-type="pmcid">PMC5142765</pub-id></mixed-citation></ref><ref id="bibr88-1179555717695548"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weisel</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Zuccarino-Catania</surname><given-names>GV</given-names></name><name name-style="western"><surname>Chikina</surname><given-names>M</given-names></name><name name-style="western"><surname>Shlomchik</surname><given-names>MJ.</given-names></name></person-group><article-title>A temporal switch in the germinal center determines differential output of memory B and plasma cells</article-title>. <source>Immunity</source>. <year>2016</year>;<volume>44</volume>:<fpage>116</fpage>&#8211;<lpage>130</lpage>.<pub-id pub-id-type="pmid">26795247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2015.12.004</pub-id><pub-id pub-id-type="pmcid">PMC4724390</pub-id></mixed-citation></ref><ref id="bibr89-1179555717695548"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gavillet</surname><given-names>BM</given-names></name><name name-style="western"><surname>Eberhardt</surname><given-names>CS</given-names></name><name name-style="western"><surname>Auderset</surname><given-names>F</given-names></name><etal/></person-group><article-title>MF59 mediates its B cell adjuvanticity by promoting T follicular helper cells and thus germinal center responses in adult and early life</article-title>. <source>J Immunol</source>. <year>2015</year>;<volume>194</volume>:<fpage>4836</fpage>&#8211;<lpage>4845</lpage>.<pub-id pub-id-type="pmid">25870238</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1402071</pub-id></mixed-citation></ref><ref id="bibr90-1179555717695548"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lofano</surname><given-names>G</given-names></name><name name-style="western"><surname>Mancini</surname><given-names>F</given-names></name><name name-style="western"><surname>Salvatore</surname><given-names>G</given-names></name><etal/></person-group><article-title>Oil-in-water emulsion MF59 increases germinal center B cell differentiation and persistence in response to vaccination</article-title>. <source>J Immunol</source>. <year>2015</year>;<volume>195</volume>:<fpage>1617</fpage>&#8211;<lpage>1627</lpage>.<pub-id pub-id-type="pmid">26170383</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1402604</pub-id></mixed-citation></ref><ref id="bibr91-1179555717695548"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaccari</surname><given-names>M</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>SN</given-names></name><name name-style="western"><surname>Fourati</surname><given-names>S</given-names></name><etal/></person-group><article-title>Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition</article-title>. <source>Nat Med</source>. <year>2016</year>;<volume>22</volume>:<fpage>762</fpage>&#8211;<lpage>770</lpage>.<pub-id pub-id-type="pmid">27239761</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.4105</pub-id><pub-id pub-id-type="pmcid">PMC5916782</pub-id></mixed-citation></ref><ref id="bibr92-1179555717695548"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirota</surname><given-names>K</given-names></name><name name-style="western"><surname>Turner</surname><given-names>J-E</given-names></name><name name-style="western"><surname>Villa</surname><given-names>M</given-names></name><etal/></person-group><article-title>Plasticity of Th17 cells in Peyer&#8217;s patches is responsible for the induction of T cell-dependent IgA responses</article-title>. <source>Nat Immunol</source>. <year>2013</year>;<volume>14</volume>:<fpage>372</fpage>&#8211;<lpage>379</lpage>.<pub-id pub-id-type="pmid">23475182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ni.2552</pub-id><pub-id pub-id-type="pmcid">PMC3672955</pub-id></mixed-citation></ref><ref id="bibr93-1179555717695548"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Milpied</surname><given-names>PJ</given-names></name><name name-style="western"><surname>McHeyzer-Williams</surname><given-names>MG.</given-names></name></person-group><article-title>High-affinity IgA needs Th17 cell functional plasticity</article-title>. <source>Nat Immunol</source>. <year>2013</year>;<volume>14</volume>:<fpage>313</fpage>&#8211;<lpage>315</lpage>.<pub-id pub-id-type="pmid">23507637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ni.2567</pub-id></mixed-citation></ref><ref id="bibr94-1179555717695548"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaul</surname><given-names>R</given-names></name><name name-style="western"><surname>Trabattoni</surname><given-names>D</given-names></name><name name-style="western"><surname>Bwayo</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers</article-title>. <source>AIDS</source>. <year>1999</year>;<volume>13</volume>:<fpage>23</fpage>&#8211;<lpage>29</lpage>.<pub-id pub-id-type="pmid">10207541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00002030-199901140-00004</pub-id></mixed-citation></ref><ref id="bibr95-1179555717695548"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devito</surname><given-names>C</given-names></name><name name-style="western"><surname>Broliden</surname><given-names>K</given-names></name><name name-style="western"><surname>Kaul</surname><given-names>R</given-names></name><etal/></person-group><article-title>Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells</article-title>. <source>J Immunol</source>. <year>2000</year>;<volume>165</volume>:<fpage>5170</fpage>&#8211;<lpage>5176</lpage>.<pub-id pub-id-type="pmid">11046049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.165.9.5170</pub-id></mixed-citation></ref><ref id="bibr96-1179555717695548"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaul</surname><given-names>R</given-names></name><name name-style="western"><surname>Plummer</surname><given-names>F</given-names></name><name name-style="western"><surname>Clerici</surname><given-names>M</given-names></name><name name-style="western"><surname>Bomsel</surname><given-names>M</given-names></name><name name-style="western"><surname>Lopalco</surname><given-names>L</given-names></name><name name-style="western"><surname>Broliden</surname><given-names>K.</given-names></name></person-group><article-title>Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection</article-title>. <source>AIDS</source>. <year>2001</year>;<volume>15</volume>:<fpage>431</fpage>&#8211;<lpage>432</lpage>.<pub-id pub-id-type="pmid">11273233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00002030-200102160-00026</pub-id></mixed-citation></ref><ref id="bibr97-1179555717695548"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirao</surname><given-names>LA</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><name name-style="western"><surname>Khan</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques</article-title>. <source>Vaccine</source>. <year>2008</year>;<volume>26</volume>:<fpage>3112</fpage>&#8211;<lpage>3120</lpage>.<pub-id pub-id-type="pmid">18430495</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2008.02.036</pub-id><pub-id pub-id-type="pmcid">PMC4477809</pub-id></mixed-citation></ref><ref id="bibr98-1179555717695548"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chong</surname><given-names>S-Y</given-names></name><name name-style="western"><surname>Egan</surname><given-names>MA</given-names></name><name name-style="western"><surname>Kutzler</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques</article-title>. <source>Vaccine</source>. <year>2007</year>;<volume>25</volume>:<fpage>4967</fpage>&#8211;<lpage>4982</lpage>.<pub-id pub-id-type="pmid">17335943</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2006.11.070</pub-id></mixed-citation></ref><ref id="bibr99-1179555717695548"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalams</surname><given-names>SA</given-names></name><name name-style="western"><surname>Parker</surname><given-names>S</given-names></name><name name-style="western"><surname>Jin</surname><given-names>X</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults</article-title>. <source>PLoS ONE</source>. <year>2012</year>;<volume>7</volume>:<fpage>e29231</fpage>.<pub-id pub-id-type="pmid">22242162</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0029231</pub-id><pub-id pub-id-type="pmcid">PMC3252307</pub-id></mixed-citation></ref><ref id="bibr100-1179555717695548"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmitt</surname><given-names>N</given-names></name><name name-style="western"><surname>Bustamante</surname><given-names>J</given-names></name><name name-style="western"><surname>Bourdery</surname><given-names>L</given-names></name><etal/></person-group><article-title>IL-12 receptor &#946;1 deficiency alters in vivo T follicular helper cell response in humans</article-title>. <source>Blood</source>. <year>2013</year>;<volume>121</volume>:<fpage>3375</fpage>&#8211;<lpage>3385</lpage>.<pub-id pub-id-type="pmid">23476048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2012-08-448902</pub-id><pub-id pub-id-type="pmcid">PMC3637013</pub-id></mixed-citation></ref><ref id="bibr101-1179555717695548"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Suh</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>AV</given-names></name><name name-style="western"><surname>Ockenhouse</surname><given-names>CF</given-names></name><name name-style="western"><surname>Yadava</surname><given-names>A</given-names></name><name name-style="western"><surname>Irvine</surname><given-names>DJ.</given-names></name></person-group><article-title>Enhancing humoral responses to a malaria antigen with RIG-I particle vaccines that expand Tfh cells and promote germinal center induction</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2012</year>;<volume>109</volume>:<fpage>1080</fpage>&#8211;<lpage>1085</lpage>.<pub-id pub-id-type="pmid">22247289</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1112648109</pub-id><pub-id pub-id-type="pmcid">PMC3268296</pub-id></mixed-citation></ref><ref id="bibr102-1179555717695548"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kulkarni</surname><given-names>RR</given-names></name><name name-style="western"><surname>Rasheed</surname><given-names>MAU</given-names></name><name name-style="western"><surname>Bhaumik</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity</article-title>. <source>J Virol</source>. <year>2014</year>;<volume>88</volume>:<fpage>13990</fpage>&#8211;<lpage>14001</lpage>.<pub-id pub-id-type="pmid">25253340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02273-14</pub-id><pub-id pub-id-type="pmcid">PMC4249139</pub-id></mixed-citation></ref><ref id="bibr103-1179555717695548"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinez-Navio</surname><given-names>JM</given-names></name><name name-style="western"><surname>Casanova</surname><given-names>V</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>R</given-names></name><etal/></person-group><article-title>Adenosine deaminase potentiates the generation of effector, memory, and regulatory CD4+ T cells</article-title>. <source>J Leukoc Biol</source>. <year>2011</year>;<volume>89</volume>:<fpage>127</fpage>&#8211;<lpage>136</lpage>.<pub-id pub-id-type="pmid">20959412</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1189/jlb.1009696</pub-id></mixed-citation></ref><ref id="bibr104-1179555717695548"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Climent</surname><given-names>N</given-names></name><name name-style="western"><surname>Martinez-Navio</surname><given-names>JM</given-names></name><name name-style="western"><surname>Gil</surname><given-names>C</given-names></name><etal/></person-group><article-title>Adenosine deaminase enhances T-cell response elicited by dendritic cells loaded with inactivated HIV</article-title>. <source>Immunol Cell Biol</source>. <year>2009</year>;<volume>87</volume>:<fpage>634</fpage>&#8211;<lpage>639</lpage>.+<pub-id pub-id-type="pmid">19668260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/icb.2009.53</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>